Search

Your search keyword '"Canonica, G.W."' showing total 198 results
Start Over Author "Canonica, G.W." Search Limiters Available in Library Collection
198 results on '"Canonica, G.W."'

1. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

Author

Bousquet, J., Sousa-Pinto, B., Anto, J.M., Amaral, R., Brussino, L., Canonica, G.W., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Louis, R., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., Chaves-Loureiro, C., Czarlewski, W., de Blay, F., Devillier, P., Joos, G., Jutel, M., Klimek, L., Kuna, P., Laune, D., Pech, J.L., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Ohta, K., Papadopoulos, N.G., Papi, A., Yeverino, D.R., Roche, N., Sá-Sousa, A., Samolinski, B., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Vandenplas, O., Yorgancioglu, A., Zuberbier, T., and Fonseca, J.A.

Published
2023
Full Text
View/download PDF

2. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

Author

Sousa-Pinto, B., Louis, R., Anto, J.M., Amaral, R., Sá-Sousa, A., Czarlewski, W., Brussino, L., Canonica, G.W., Chaves Loureiro, C., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Okamoto, Y., Ollert, M., Pfaar, O., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Becker, S., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., de Blay, F., Del Giacco, S., Ivancevich, J.C., Jutel, M., Klimek, L., Kraxner, H., Kuna, P., Laune, D., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Papadopoulos, N.G., Papi, A., Patella, V., Pétré, B., Rivero Yeverino, D., Robalo Cordeiro, C., Roche, N., Rouadi, P.W., Samolinski, B., Savouré, M., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Fonseca, J.A., Costa, E.M., and Bousquet, J.

Published
2023
Full Text
View/download PDF

8. EUFOREA treatment algorithm for allergic rhinitis.

Author

Hellings P.W., Bachert C., Bjermer L., Canonica G.W., Cardell L.O., Carney A.S., Constantinidis J., Deneyer L., Diamant Z., Durham S., Gevaert P., Harvey R., Hopkins C., Kjeldsen A., Klimek L., Lund V.J., Price D., Rimmer J., Ryan D., Roberts G., Sahlstrand-Johnson P., Salmi S., Samji M., Scadding G., Smith P., Steinsvik A., Wagenmann M., Seys S., Wahn U., Fokkens W.J., Hellings P.W., Bachert C., Bjermer L., Canonica G.W., Cardell L.O., Carney A.S., Constantinidis J., Deneyer L., Diamant Z., Durham S., Gevaert P., Harvey R., Hopkins C., Kjeldsen A., Klimek L., Lund V.J., Price D., Rimmer J., Ryan D., Roberts G., Sahlstrand-Johnson P., Salmi S., Samji M., Scadding G., Smith P., Steinsvik A., Wagenmann M., Seys S., Wahn U., and Fokkens W.J.

Published
2022

9. Development and validation of combined symptom-medication scores for allergic rhinitis*

Author

Sousa-Pinto, B. Azevedo, L.F. Jutel, M. Agache, I. Canonica, G.W. Czarlewski, W. Papadopoulos, N.G. Bergmann, K.-C. Devillier, P. Laune, D. Klimek, L. Anto, A. Anto, J.M. Eklund, P. Almeida, R. Bedbrook, A. Bosnic-Anticevich, S. Brough, H.A. Brussino, L. Cardona, V. Casale, T. Cecchi, L. Charpin, D. Chivato, T. Costa, E.M. Cruz, A.A. Dramburg, S. Durham, S.R. De Feo, G. Gerth van Wijk, R. Fokkens, W.J. Gemicioglu, B. Haahtela, T. Illario, M. Ivancevich, J.C. Kvedariene, V. Kuna, P. Larenas-Linnemann, D.E. Makris, M. Mathieu-Dupas, E. Melén, E. Morais-Almeida, M. Mösges, R. Mullol, J. Nadeau, K.C. Pham-Thi, N. O’Hehir, R. Regateiro, F.S. Reitsma, S. Samolinski, B. Sheikh, A. Stellato, C. Todo-Bom, A. Tomazic, P.V. Toppila-Salmi, S. Valero, A. Valiulis, A. Ventura, M.T. Wallace, D. Waserman, S. Yorgancioglu, A. De Vries, G. van Eerd, M. Zieglmayer, P. Zuberbier, T. Pfaar, O. Almeida Fonseca, J. Bousquet, J.

Abstract

Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials. © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2022

10. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

Author

Sousa-Pinto, B. Azevedo, L.F. Sá-Sousa, A. Vieira, R.J. Amaral, R. Klimek, L. Czarlewski, W. Anto, J.M. Bedbrook, A. Kvedariene, V. Ventura, M.T. Ansotegui, I.J. Bergmann, K.-C. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Casale, T. Cecchi, L. Chivato, T. Chu, D.K. Cingi, C. Costa, E.M. Cruz, A.A. De Feo, G. Devillier, P. Fokkens, W.J. Gaga, M. Gemicioğlu, B. Haahtela, T. Ivancevich, J.C. Ispayeva, Z. Jutel, M. Kuna, P. Kaidashev, I. Kraxner, H. Larenas-Linnemann, D.E. Laune, D. Lipworth, B. Louis, R. Makris, M. Monti, R. Morais-Almeida, M. Mösges, R. Mullol, J. Odemyr, M. Okamoto, Y. Papadopoulos, N.G. Patella, V. Pham-Thi, N. Regateiro, F.S. Reitsma, S. Rouadi, P.W. Samolinski, B. Sova, M. Todo-Bom, A. Taborda-Barata, L. Tomazic, P.V. Toppila-Salmi, S. Sastre, J. Tsiligianni, I. Valiulis, A. Wallace, D. Waserman, S. Yorgancioglu, A. Zidarn, M. Zuberbier, T. Fonseca, J.A. Bousquet, J. Pfaar, O.

Abstract

Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness. © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Published
2022

11. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Author

Porsbjerg, C.M. Menzies-Gow, A.N. Tran, T.N. Murray, R.B. Unni, B. Audrey Ang, S.L. Alacqua, M. Al-Ahmad, M. Al-Lehebi, R. Altraja, A. Belevskiy, A.S. Björnsdóttir, U.S. Bourdin, A. Busby, J. Canonica, G.W. Christoff, G.C. Cosio, B.G. Costello, R.W. FitzGerald, J.M. Fonseca, J.A. Hansen, S. Heaney, L.G. Heffler, E. Hew, M. Iwanaga, T. Jackson, D.J. Kocks, J.W.H. Kallieri, M. Bruce Ko, H.-K. Koh, M.S. Larenas-Linnemann, D. Lehtimäki, L.A. Loukides, S. Lugogo, N. Maspero, J. Papaioannou, A.I. Perez-de-Llano, L. Pitrez, P.M. Popov, T.A. Rasmussen, L.M. Rhee, C.K. Sadatsafavi, M. Schmid, J. Siddiqui, S. Taillé, C. Taube, C. Torres-Duque, C.A. Ulrik, C. Upham, J.W. Wang, E. Wechsler, M.E. Bulathsinhala, L. Carter, V. Chaudhry, I. Eleangovan, N. Hosseini, N. Rowlands, M.-A. Price, D.B. van Boven, J.F.M.

Abstract

Background: Regulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine. Objective: To compare global differences in ease of access to biologics. Methods: In April 2021, national prescription criteria for omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab were reviewed by severe asthma experts collaborating in the International Severe Asthma Registry. Outcomes (per country, per biologic) were (1) country-specific prescription criteria and (2) development of the Biologic Accessibility Score (BACS). The BACS composite score incorporates 10 prescription criteria, each with a maximum score of 10 points. Referenced to European Medicines Agency marketing authorization specifications, a higher score reflects easier access. Results: Biologic prescription criteria differed substantially across 28 countries from five continents. Blood eosinophil count thresholds (usually ≥300 cells/μL) and exacerbations were key requirements for anti-IgE/anti–IL-5/5R prescriptions in around 80% of licensed countries. Most countries (40% for dupilumab to 54% for mepolizumab) require two or more moderate or severe exacerbations, whereas numbers ranged from none to four. Moreover, 0% (for reslizumab) to 21% (for omalizumab) of countries required long-term oral corticosteroid use. The BACS highlighted marked between-country differences in ease of access. For omalizumab, mepolizumab, benralizumab, and dupilumab, only two, one, four, and seven countries, respectively, scored equal or higher than the European Medicines Agency reference BACS. For reslizumab, all countries scored lower. Conclusions: Although some differences were expected in country-specific biologic prescription criteria and ease of access, the substantial differences found in the current study present a challenge to implementing precision medicine across the world. © 2022 The Authors

Published
2022

12. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data

Author

Sousa-Pinto, B. Sá-Sousa, A. Vieira, R.J. Amaral, R. Klimek, L. Czarlewski, W. Antó, J.M. Pfaar, O. Bedbrook, A. Kvedariene, V. Ventura, M.T. Ansotegui, I.J. Bergmann, K.-C. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Casale, T. Cecchi, L. Chivato, T. Chu, D.K. Cingi, C. Costa, E.M. Cruz, A.A. De Feo, G. Devillier, P. Fokkens, W.J. Gaga, M. Gemicioğlu, B. Haahtela, T. Ivancevich, J.C. Ispayeva, Z. Jutel, M. Kuna, P. Kaidashev, I. Kraxner, H. Larenas-Linnemann, D.E. Laune, D. Lipworth, B. Louis, R. Makris, M. Monti, R. Morais-Almeida, M. Mösges, R. Mullol, J. Odemyr, M. Okamoto, Y. Papadopoulos, N.G. Patella, V. Pham-Thi, N. Regateiro, F.S. Reitsma, S. Rouadi, P.W. Samolinski, B. Sova, M. Todo-Bom, A. Taborda-Barata, L. Tomazic, P.V. Toppila-Salmi, S. Sastre, J. Tsiligianni, I. Valiulis, A. Vandenplas, O. Wallace, D. Waserman, S. Yorgancioglu, A. Zidarn, M. Zuberbier, T. Fonseca, J.A. Bousquet, J.

Abstract

Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015–2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (‘VAS Global Symptoms’) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median ‘VAS Global Symptoms’ was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p

Published
2022

14. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19

Author

Bousquet, J. Czarlewski, W. Zuberbier, T. Mullol, J. Blain, H. Cristol, J.-P. De La Torre, R. Pizarro Lozano, N. Le Moing, V. Bedbrook, A. Agache, I. Akdis, C.A. Canonica, G.W. Cruz, A.A. Fiocchi, A. Fonseca, J.A. Fonseca, S. Gemicioǧlu, B. Haahtela, T. Iaccarino, G. Ivancevich, J.C. Jutel, M. Klimek, L. Kraxner, H. Kuna, P. Larenas-Linnemann, D.E. Martineau, A. Melén, E. Okamoto, Y. Papadopoulos, N.G. Pfaar, O. Regateiro, F.S. Reynes, J. Rolland, Y. Rouadi, P.W. Samolinski, B. Sheikh, A. Toppila-Salmi, S. Valiulis, A. Choi, H.-J. Kim, H.J. Anto, J.M.

Subjects
nervous system, musculoskeletal, neural, and ocular physiology, food and beverages, psychological phenomena and processes
Abstract

In this article, we propose that differences in COVID-19 morbidity may be associated with transient receptor potential ankyrin 1 (TRPA1) and/or transient receptor potential vanilloid 1 (TRPV1) activation as well as desensitization. TRPA1 and TRPV1 induce inflammation and play a key role in the physiology of almost all organs. They may augment sensory or vagal nerve discharges to evoke pain and several symptoms of COVID-19, including cough, nasal obstruction, vomiting, diarrhea, and, at least partly, sudden and severe loss of smell and taste. TRPA1 can be activated by reactive oxygen species and may therefore be up-regulated in COVID-19. TRPA1 and TRPV1 channels can be activated by pungent compounds including many nuclear factor (erythroid-derived 2) (Nrf2)-interacting foods leading to channel desensitization. Interactions between Nrf2-associated nutrients and TRPA1/TRPV1 may be partly responsible for the severity of some of the COVID-19 symptoms. The regulation by Nrf2 of TRPA1/TRPV1 is still unclear, but suggested from very limited clinical evidence. In COVID-19, it is proposed that rapid desensitization of TRAP1/TRPV1 by some ingredients in foods could reduce symptom severity and provide new therapeutic strategies. © 2021 S. Karger AG, Basel.

Published
2021

15. Spices to Control COVID-19 Symptoms: Yes, but Not Only

Author

Bousquet, J. Czarlewski, W. Zuberbier, T. Mullol, J. Blain, H. Cristol, J.-P. De La Torre, R. Le Moing, V. Lozano, N.P. Bedbrook, A. Agache, I. Akdis, C.A. Canonica, G.W. Cruz, A.A. Fiocchi, A. Fonseca, J.A. Fonseca, S. Gemicioǧlu, B. Haahtela, T. Iaccarino, G. Ivancevich, J.C. Jutel, M. Klimek, L. Kuna, P. Larenas-Linnemann, D.E. Melén, E. Okamoto, Y. Papadopoulos, N.G. Pfaar, O. Reynes, J. Rolland, Y. Rouadi, P.W. Samolinski, B. Sheikh, A. Toppila-Salmi, S. Valiulis, A. Choi, H.-J. Kim, H.J. Anto, J.M.

Abstract

There are large country variations in COVID-19 death rates that may be partly explained by diet. Many countries with low COVID-19 death rates have a common feature of eating large quantities of fermented vegetables such as cabbage and, in some continents, various spices. Fermented vegetables and spices are agonists of the antioxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), and spices are transient receptor potential ankyrin 1 and vanillin 1 (TRPA1/V1) agonists. These mechanisms may explain many COVID-19 symptoms and severity. It appears that there is a synergy between Nrf2 and TRPA1/V1 foods that may explain the role of diet in COVID-19. One of the mechanisms of COVID-19 appears to be an oxygen species (ROS)-mediated process in synergy with TRP channels, modulated by Nrf2 pathways. Spicy foods are likely to desensitize TRP channels and act in synergy with exogenous antioxidants that activate the Nrf2 pathway. © 2020

Published
2021

16. EAACI Biologicals Guidelines—Recommendations for severe asthma

Author

Agache, I. Akdis, C.A. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Chu, D.K. Del Giacco, S. Eiwegger, T. Flood, B. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Hernández-Martín, I. Knibb, R. Mäkelä, M. Nair, P. O’Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Pfaar, O. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Palomares, O. Jutel, M.

Abstract

Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

17. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Author

Pfaar, O. Klimek, L. Jutel, M. Akdis, C.A. Bousquet, J. Breiteneder, H. Chinthrajah, S. Diamant, Z. Eiwegger, T. Fokkens, W.J. Fritsch, H.-W. Nadeau, K.C. O’Hehir, R.E. O’Mahony, L. Rief, W. Sampath, V. Schedlowski, M. Torres, M.J. Traidl-Hoffmann, C. Wang, D.Y. Zhang, L. Bonini, M. Brehler, R. Brough, H.A. Chivato, T. Del Giacco, S.R. Dramburg, S. Gawlik, R. Gelincik, A. Hoffmann-Sommergruber, K. Hox, V. Knol, E.F. Lauerma, A. Matricardi, P.M. Mortz, C.G. Ollert, M. Palomares, O. Riggioni, C. Schwarze, J. Skypala, I. Untersmayr, E. Walusiak-Skorupa, J. Ansotegui, I.J. Bachert, C. Bedbrook, A. Bosnic-Anticevich, S. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Cruz, A.A. Czarlewski, W. Fonseca, J.A. Gotua, M. Haahtela, T. Ivancevich, J.C. Kuna, P. Kvedariene, V. Larenas-Linnemann, D.E. Abdul Latiff, A.H. Mäkelä, M. Morais-Almeida, M. Mullol, J. Naclerio, R. Ohta, K. Okamoto, Y. Onorato, G.L. Papadopoulos, N.G. Patella, V. Regateiro, F.S. Samoliński, B. Suppli Ulrik, C. Toppila-Salmi, S. Valiulis, A. Ventura, M.-T. Yorgancioglu, A. Zuberbier, T. Agache, I.

Subjects
education
Abstract

Background: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. Results: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

18. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Bousquet, J. Agache, I. Blain, H. Jutel, M. Ventura, M.T. Worm, M. Del Giacco, S. Benetos, A. Bilo, B.M. Czarlewski, W. Abdul Latiff, A.H. Al-Ahmad, M. Angier, E. Annesi-Maesano, I. Atanaskovic-Markovic, M. Bachert, C. Barbaud, A. Bedbrook, A. Bennoor, K.S. Berghea, E.C. Bindslev-Jensen, C. Bonini, S. Bosnic-Anticevich, S. Brockow, K. Brussino, L. Camargos, P. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Carriazo, A. Casale, T. Caubet, J.-C. Cecchi, L. Cherubini, A. Christoff, G. Chu, D.K. Cruz, A.A. Dokic, D. El-Gamal, Y. Ebisawa, M. Eberlein, B. Farrell, J. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J.A. Gao, Y. Gavazzi, G. Gawlik, R. Gelincik, A. Gemicioğlu, B. Gotua, M. Guérin, O. Haahtela, T. Hoffmann-Sommergruber, K. Hoffmann, H.J. Hofmann, M. Hrubisko, M. Illario, M. Irani, C. Ispayeva, Z. Ivancevich, J.C. Julge, K. Kaidashev, I. Khaitov, M. Knol, E. Kraxner, H. Kuna, P. Kvedariene, V. Lauerma, A. Le, L.T.T. Le Moing, V. Levin, M. Louis, R. Lourenco, O. Mahler, V. Martin, F.C. Matucci, A. Milenkovic, B. Miot, S. Montella, E. Morais-Almeida, M. Mortz, C.G. Mullol, J. Namazova-Baranova, L. Neffen, H. Nekam, K. Niedoszytko, M. Odemyr, M. O’Hehir, R.E. Okamoto, Y. Ollert, M. Palomares, O. Papadopoulos, N.G. Panzner, P. Passalacqua, G. Patella, V. Petrovic, M. Pfaar, O. Pham-Thi, N. Plavec, D. Popov, T.A. Recto, M.T. Regateiro, F.S. Reynes, J. Roller-Winsberger, R.E. Rolland, Y. Romano, A. Rondon, C. Rottem, M. Rouadi, P.W. Salles, N. Samolinski, B. Santos, A.F. S Sarquis, F. Sastre, J. M. G. A. Schols, J. Scichilone, N. Sediva, A. Shamji, M.H. Sheikh, A. Skypala, I. Smolinska, S. Sokolowska, M. Sousa-Pinto, B. Sova, M. Stelmach, R. Sturm, G. Suppli Ulrik, C. Todo-Bom, A.M. Toppila-Salmi, S. Tsiligianni, I. Torres, M. Untersmayr, E. Urrutia Pereira, M. Valiulis, A. Vitte, J. Vultaggio, A. Wallace, D. Walusiak-Skorupa, J. Wang, D.-Y. Waserman, S. Yorgancioglu, A. Yusuf, O.M. Zernotti, M. Zidarn, M. Chivato, T. Akdis, C.A. Zuberbier, T. Klimek, L.

Abstract

Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

19. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

Author

Bousquet, J. Anto, J.M. Iaccarino, G. Czarlewski, W. Haahtela, T. Anto, A. Akdis, C.A. Blain, H. Canonica, G.W. Cardona, V. Cruz, A.A. Illario, M. Ivancevich, J.C. Jutel, M. Klimek, L. Kuna, P. Laune, D. Larenas-linnemann, D. Mullol, J. Papadopoulos, N.G. Pfaar, O. Samolinski, B. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Latiff, A.H.A. Abdullah, B. Aberer, W. Abusada, N. Adcock, I. Afani, A. Agache, I. Aggelidis, X. Agustin, J. Akdis, C. Akdis, M. Al-Ahmad, M. Bassam, A.A.-Z. Aldrey-Palacios, O. Cuesta, E.A. Alzaabi, A. Amad, S. Ambrocio, G. Annesi-Maesano, I. Ansotegui, I. Anto, J. Arshad, H. Artesani, M.C. Asayag, E. Avolio, F. Azhari, K. Baiardini, I. Bajrović, N. Bakakos, P. Mongono, S.B. Balotro-Torres, C. Barba, S. Barbara, C. Barbosa, E. Barreto, B. Bartra, J. Bateman, E.D. Battur, L. Bedbrook, A. Barajas, M.B. Beghé, B. Bel, E. Kheder, A.B. Benson, M. Berghea, C. Bergmann, K.-C. Bernstein, D. Bewick, M. Bialek, S. Białoszewski, A. Bieber, T. Billo, N. Bilo, M.B. Bindslev-Jensen, C. Bjermer, L. Blain, H. Marciniak, M.B. Bond, C. Boner, A. Bonini, M. Bonini, S. Bosnic-Anticevich, S. Bosse, I. Botskariova, S. Bouchard, J. Boulet, L.-P. Bourret, R. Bousquet, P. Braido, F. Briggs, A. Brightling, C. Brozek, J. Buhl, R. Bumbacea, R. Cabañas, M.T.B. Bush, A. Busse, W.W. Buters, J. Caballero-Fonseca, F. Calderon, M.A. Calvo, M. Camargos, P. Camuzat, T. Cano, A. Capriles-Hulett, A. Caraballo, L. Cardona, V. Carlsen, K.-H. Caro, J. Carr, W. Carreon-Asun-cion, F. Carriazo, A.M. Casale, T. Castor, M.A. Castro, E. Cecchi, L. Sarabia, A.C. Chandrasekharan, R. Chang, Y.-S. Chato-Andeza, V. Chatzi, L. Chatzidaki, C. Chavannes, N.H. Chen, Y. Cheng, L. Chivato, T. Chkhartishvili, E. Christoff, G. Chrystyn, H. Chu, D.K. Chua, A. Chuchalin, A. Chung, K.F. Cicerán, A. Cingi, C. Ciprandi, G. Cirule, I. Coelho, A.C. Constantinidis, J. Sousa, J.C. Costa, E. Costa, D. Domínguez, M.C.C. Coste, A. Cox, L. Cruz, A.A. Cullen, J. Custovic, A. Cvetkovski, B. Czarlewski, W. D’amato, G. Silva, J.D. Dahl, R. Dahlen, S.-E. Daniilidis, V. Nahhas, L.D. Darsow, U. Blay, F. Guia, E.D. Santos, C. Keenoy, E.D.M. Vries, G.D. Deleanu, D. Demoly, P. Denburg, J. Devillier, P. Didier, A. Dimou, M. Dinh-Xuan, A.T. Djukanovic, R. Dokic, D. Silva, M.G.D. Douagui, H. Douladiris, N. Doulaptsi, M. Dray, G. Dubakiene, R. Durham, S. Dykewicz, M. Ebo, D. Edelbaher, N. Eklund, P. El-Gamal, Y. El-Sayed, Z.A. El-Sayed, S.S. El-Seify, M. Emuzyte, R. Enecilla, L. Espinoza, H. Farrell, J. Fernandez, L. Wagner, A.F. Fiocchi, A. Fokkens, W.J. Fontaine, J.-F. Forastiere, F. Fuentes, J.M. Gaerlan–resureccion, E. Gaga, M. Romero, J.L.G. Gamkrelidze, A. Garcia, A. Cobas, C.Y.G. Gayraud, J. Gemicioglu, B. Genova, S. Gereda, J. Wijk, R.G. Gomez, M. Diaz, S.G. Gotua, M. Grigoreas, C. Grisle, I. Guidacci, M. Guldemond, N. Gutter, Z. Guzmán, A. Haahtela, T. Halloum, R. Hamelmann, E. Hammadi, S. Harvey, R. Heinrich, J. Hejjaoui, A. Hellquist-Dahl, B. Velázquez, L.H. Hew, M. Hossny, E. Howarth, P. Hrubiško, M. Villalobos, Y.R.H. Humbert, M. Hyland, M. Iaccarino, G. Ibrahim, M. Illario, M. Ilyina, N. Irani, C. Ispayeva, Z. Ivancevich, J.C. Jares, E. Jarvis, D. Jassem, E. Jenko, K. Uscanga, R.D.J. Johnston, S. Joos, G. Jošt, M. Julge, K. Jung, K.-S. Just, J. Jutel, M. Kaidashev, I. Kalayci, O. Kalyoncu, F. Kapsali, J. Kardas, P. Karjalainen, J. Kasala, C.A. Katotomichelakis, M. Kazi, B. Keil, T. Keith, P. Khaitov, M. Khaltaev, N. Kim, Y.-Y. Kleine-Tebbe, J. Klimek, L. Koffi N’Goran, B. Kompoti, E. Kopač, P. Koppelman, G. Jeverica, A.K. Košnik, M. Kostov, K.V. Kowalski, M.L. Kralimarkova, T. Vrščaj, K.K. Kraxner, H. Kreft, S. Kritikos, V. Kudlay, D. Kull, I. Kuna, P. Kupczyk, M. Kvedariene, V. Kyriakakou, M. Lalek, N. Lane, S. Larenas-Linnemann, D. Latiff, A. Lau, S. Laune, D. Lavrut, J. Le, L. Lessa, M. Levin, M. Li, J. Lieberman, P. Liotta, G. Lipworth, B. Liu, X. Lobo, R. Lodrup Carlsen, K.C. Lombardi, C. Louis, R. Loukidis, S. Lourenço, O. Luna Pech, J.A. Madjar, B. Magnan, A. Mahboub, B. Mair, A. Mais, Y. van der Zee, A.-H.M. Makela, M. Makris, M. Malling, H.-J. Mandajieva, M. Manning, P. Manousakis, M. Maragoudakis, P. Marshall, G. Martins, P. Masjedi, M.R. Máspero, J.F. Campos, J.J.M. Maurer, M. Mavale-Manuel, S. Meço, C. Melén, E. Melo-Gomes, E. Meltzer, E.O. Menditto, E. Menzies-Gow, A. Merk, H. Michel, J.-P. Miculinic, N. Midão, L. Mihaltan, F. Mikael, K. Mikos, N. Milenkovic, B. Mitsias, D. Moalla, B. Moda, G. Martínez, M.D.M. Mohammad, Y. Moin, M. Molimard, M. Momas, I. Monaco, A. Montefort, S. Mora, D. Morais-Almeida, M. Mösges, R. Mostafa, B.E. Mullol, J. Münter, L. Muraro, A. Murray, R. Mustakov, T. Naclerio, R. Nadif, R. Nakonechna, A. Namazova-Baranova, L. Navarro-Locsin, G. Neffen, H. Nekam, K. Neou, A. Nicod, L. Niederberger-Leppin, V. Niedoszytko, M. Nieto, A. Novellino, E. Nunes, E. Nyembue, D. O’hehir, R. Odjakova, C. Ohta, K. Okamoto, Y. Okubo, K. Oliver, B. Onorato, G.L. Orru, M.P. Ouédraogo, S. Ouoba, K. Paggiaro, P.L. Pagkalos, A. Palaniappan, S.P. Pali-Schöll, I. Palkonen, S. Palmer, S. Bunu, C.P. Panzner, P. Papadopoulos, N.G. Papanikolaou, V. Papi, A. Paralchev, B. Paraskevopoulos, G. Park, H.S. Passalacqua, G. Patella, V. Pavord, I. Pawankar, R. Pedersen, S. Peleve, S. Pereira, A. Pérez, T. Pfaar, O. Pham-Thi, N. Pigearias, B. Pin, I. Piskou, K. Pitsios, C. Pitsios, K. Plavec, D. Poethig, D. Pohl, W. Susic, A.P. Popov, T.A. Portejoie, F. Potter, P. Poulsen, L. Prados-Torres, A. Prarros, F. Price, D. Prokopakis, E. Puy, R. Rabe, K. Raciborski, F. Ramos, J. Recto, M.T. Reda, S.M. Regateiro, F. Reider, N. Reitsma, S. Repka-Ramirez, S. Rimmer, J. Yeverino, D.R. Rizzo, J.A. Robalo-Cordeiro, C. Roberts, G. Roche, N. González, M.R. Zagal, E.R. Rolland, C. Roller-Wirns-berger, R. Rodriguez, M.R. Romano, A. Rombaux, P. Romualdez, J. Rosado-Pinto, J. Rosario, N. Rosenwasser, L. Rottem, M. Rouadi, P. Rovina, N. Sinur, I.R. Ruiz, M. Segura, L.T.R. Ryan, D. Sagara, H. Sakai, D. Sakurai, D. Saleh, W. Salimaki, J. Salina, H. Samitas, K.-N. Coronel, M.G.S. Sanchez-Borges, M. Sanchez-Lopez, J. Sarafoleanu, C. Serpa, F.S. Sastre-Dominguez, J. Scadding, G. Scheire, S. Schmid-Grendelmeier, P. Schuhl, J.F. Schunemann, H. Schvalbová, M. Scichilone, N. Sepúlveda, C. Serrano, E. Sheikh, A. Shields, M. Shishkov, V. Siafakas, N. Simeonov, A. Simons, E.F. Sisul, J.C. Sitkauskiene, B. Skrindo, I. Soklič, T. Solé, D. Sooronbaev, T. Soto-Martinez, M. Sova, M. Spertini, F. Spranger, O. Stamataki, S. Stefanaki, L. Stellato, C. Stelmach, R. Sterk, P. Strandberg, T. Stute, P. Subramaniam, A. Ulrik, C.S. Sutherland, M. Sylvestre, S. Syrigou, A. Barata, L.T. Takovska, N. Tan, R. Tan, F. Tan, V. Tang, I.P. Taniguchi, M. Tannert, L. Tattersall, J. Teixeira, M.D.C. Thijs, C. Thomas, M. To, T. Todo-Bom, A.M. Togias, A. Tomazic, P.-V. Toppila-Salmi, S. Toskala, E. Triggiani, M. Triller, N. Triller, K. Tsiligianni, I. Ulmeanu, R. Urbancic, J. Pereira, M.U. Vachova, M. Valdés, F. Valenta, R. Rostan, M.V. Valero, A. Valiulis, A. Vallianatou, M. Valovirta, E. Eerd, M.V. Ganse, E.V. Hage, M. Vandenplas, O. Vasankari, T. Vassileva, D. Ventura, M.T. Vera-Munoz, C. Vicheva, D. Vichyanond, P. Vidgren, P. Viegi, G. Vogelmeier, C. Hertzen, L.V. Vontetsianos, T. Vourdas, D. Wagenmann, M. Walker, S. Wallace, D. Wang, D.Y. Waserman, S. Wickman, M. Williams, S. Williams, D. Wilson, N. Woo, K. Wright, J. Wroczynski, P. Xepapadaki, P. Yakovliev, P. Yamaguchi, M. Yan, K. Yap, Y.Y. Yawn, B. Yiallouros, P. Yorgancioglu, A. Yoshihara, S. Young, I. Yusuf, O.B. Zaidi, A. Zaitoun, F. Zar, H. Zernotti, M. Zhang, L. Zhong, N. Zidarn, M. Zuberbier, T.

Abstract

Following publication of the original article [1], the authors identified an error in the affiliation list. The affiliation of author G. Walter Canonica should have been split up into two affiliations: • Personalized Medicine, Asthma and Allergy – Humanitas Clinical and Research Center – IRCCS, Rozzano (MI), Italy • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy The corrected affiliation list is reflected in this Correction. © 2020, The Author(s).

Published
2020

20. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

Author

Bousquet, J. Akdis, C.A. Jutel, M. Bachert, C. Klimek, L. Agache, I. Ansotegui, I.J. Bedbrook, A. Bosnic-Anticevich, S. Canonica, G.W. Chivato, T. Cruz, A.A. Czarlewski, W. Del Giacco, S. Du, H. Fonseca, J.A. Gao, Y. Haahtela, T. Hoffmann-Sommergruber, K. Ivancevich, J.-C. Khaltaev, N. Knol, E.F. Kuna, P. Larenas-Linnemann, D. Mullol, J. Naclerio, R. Ohta, K. Okamoto, Y. O’Mahony, L. Onorato, G.L. Papadopoulos, N.G. Pfaar, O. Samolinski, B. Schwarze, J. Toppila-Salmi, S. Ventura, M.-T. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Pawankar, R. Mubeccel, A. Mona, A.-A. Emilio, A.C. Hasan, A. Cristina, A.M. Zeinab, A. Mostafa, B.E. Sergio, B. Cristina, B. Eric, B. Bianca, B. Elisabeth, B. Larl-Christian, B. David, B. Leif, B. Attilio, B. Sergio, B. isabelle, B. Jacques, B. Louis-Philippe, B. Fulvio, B. Christopher, B. Roland, B. Carmen, B. Andrew, B. William, B. Fernan, C.-F. Davide, C. Silvia, C. Paulo, C. Walter, C. Vicky, C. Kai-Hakon, C. Warner, C. Thomas, C. Lorenzo, C. Alfonso, C.M. Niels, C. Ekaterine, C. George, C. Derek, C. Cemal, C. Giorgio, C. Ieva, C. Sousa Jaime, C.D. Maria del Carmen, C.D. André, C. Linda, C. Alvaro, C. Adnan, C. Ulf, D. Frédéric, D.B. Diana, D. Pascal, D. Philippe, D. Alain, D. Ratko, D. Maria, D.C.T. Dejan, D. Ruta, D. Stephen, D. Patrik, E. Yehia, E.-G. Regina, E. Bieren Julia, E.-V. Alessandro, F. Wytske, F. Mina, G. Luis, G.R.J. Bilun, G. Sonya, G. José, G. Maximiliano, G. Maia, G. Ineta, G. Marta, G. Antonieta, G.M. Adnan, H. Elham, H. Jonathan, H. Martin, H. Yunuen, H.V. Guido, I. Carla, I. Zhanat, I. Edgardo, J. Ewa, J. Erika, J.-J. Sebastian, J. Guy, J. Ki-Suck, J. Jocelyne, J. Igor, K. Omer, K. Fuat, K. Przemyslaw, K. Jussi, K. Jorg, K.-T. Gerard, K. Marek, K. Mikael, K. Violeta, K. Amir, L. Susanne, L. Lan, L. Marcus, L. Michael, L. Jing, L. Philip, L. Brian, L. Karin, L.C. Bassam, M. Mika, M. Hans-Jorgen, M. Gailen, M. Pedro, M. Mohammad, M. Juan-José, M. Cem, M. Erik, M. Eli, M. Hans, M. Jean-Pierre, M. Florin, M. Neven, M. Branislava, M. Yousser, M. Mathieu, M. Mario, M.-A. Ralph, M. Lars, M. Antonella, M. Tihomir, M. Alla, N. Leyla, N.-B. Kristof, N. Laurent, N. Robyn, O. Kimihiro, O. Brian, O. Luigi, P.P. Isabella, P.-S. Petr, P. Nilos, P. Sim, P.H. Ruby, P. Ana, P. Bernard, P. Constantinos, P. Davor, P. Wolfgang, P. Todor, P. Fabienne, P. Paul, P. Lars, P. Emmanuel, P. Claus, R. Stella, R.M. Janet, R. José Angelo, R. Graham, R. Nicolas, R. Antonino, R. Jose, R.-P. Nelson, R. Lanny, R. Philip, R. Dermot, R. Mario, S.-B. Joaquin, S.-D. Glenis, S. Elie, S. Nikolaos, S. Estelle, S. Juan-Carlos, S. Dirceu, S. Talant, S. Manuel, S.-M. Cristiana, S. Rafael, S. Timo, S. Charlotte, S.U. Carel, T. Peter-Valentin, T. Massimo, T. Ioana, T. Marilyn, U.P. Erkka, V. Eric, V.G. Marianne, V.H. Olivier, V. Petra, V. Martin, W. Dana, W. Yun, W.D. Susan, W. Magnus, W. Dennis, W. Barbara, Y. Arzu, Y. Osman, Y. Mario, Z. Mihaela, Z. the ARIA-MASK Study Group

Published
2020

21. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Author

Agache, I. Rocha, C. Beltran, J. Song, Y. Posso, M. Solà, I. Alonso-Coello, P. Akdis, C. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Martín, I.H. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Canelo-Aybar, C. Palomares, O. Jutel, M.

Abstract

Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) vs standard of care for patients with uncontrolled severe allergic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. All three biologicals reduced with high certainty the annualized asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50 − 0.81); dupilumab IRR 0.58 (95%CI 0.47 − 0.73); and omalizumab IRR 0.56 (95%CI 0.42 − 0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty; however, none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug-related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6-12 years old omalizumab decreased the annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 −1.83)], reduced ICS [mean difference (MD) −0.45 (95% CI −0.58 to −0.32)] and rescue medication use [MD −0.41 (95%CI −0.66 to −0.15)]. © 2020 John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

22. ARIA Guideline 2019: Treatment of allergic rhinitis in the German health system [ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem]

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Published
2020

23. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

Author

Bousquet, J. and Farrell, J. and Onorato, G.L. and Bedbrook, A. and Czarlewski, W. and Micheli, Y. and Arnavielhe, S. and Illario, M. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Basagaña, X. and Bédard, A. and Benveniste, S. and Bergmann, K.C. and Bewick, M. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bosnic-Anticevich, S. and Bosse, I. and Braido, F. and Brussino, L. and Camuzat, T. and Canonica, G.W. and Cardona, V. and Carreiro Martins, P. and Cecchi, L. and Chavannes, N.H. and Chu, D.K. and Correia da Sousa, J. and Costa, D.J. and Costa, E. and Cruz, A.A. and da Silva, J. and Devillier, P. and de Feo, G. and de Vries, G. and Dray, G. and Ebisawa, M. and Erhola, M. and Fauquert, J.L. and Fokkens, W.J. and Fonseca, J. and Fontaine, J.M. and Gemicioğlu, B. and Haahtela, T. and Heffler, E. and Hellings, P.W. and Ivancevich, J.C. and Jassem, E. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Klimek, L. and Kowalski, M.L. and Kull, I. and Kuna, P. and Kvedariene, V. and la Grutta, S. and Laune, D. and Larenas-Linnemann, D. and Ierodiakonou, D. and Le, L.T.T. and Lourenço, O. and Makris, M. and Menditto, E. and Monti, R. and Morais-Almeida, M. and Münter, L. and Muraro, A. and Murray, R. and Maurer, M. and Melén, E. and Mösges, R. and Mullol, J. and Niedoszytko, M. and O'Hehir, R.E. and Okamoto, Y. and Papadopoulos, N.G. and Passalacqua, G. and Patella, V. and Pereira, A.M. and Pfaar, O. and Pham-Thi, N. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Psarros, F. and Raciborski, F. and Regateiro, F. and Reitsma, S. and Roche, N. and Rolland, C. and Ryan, D. and Samolinski, B. and Sastre, J. and Scadding, G.K. and Schmid-Grendelmeier, P. and Schünemann, H.J. and Shamji, M. and Sheikh, A. and Stellato, C. and Suppli-Ulrik, C. and Somekh, D. and Sova, M. and Todo Bom, A. and Tomazic, P.V. and Toppila-Salmi, S. and Triggiani, M. and Tsiligianni, I. and Valero, A. and Valiulis, A. and Valovirta, E. and van Eerd, M. and Vasankari, T. and Ventura, M.T. and Wallace, D. and Waserman, S. and Yorgancioglu, A. and Zidarn, M. and Zuberbier, T., CHU Arnaud de Villeneuve, Montpellier, France, MACVIA-France, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, LANUA International Healthcare Consultancy, Belfast, Northern Ireland, United Kingdom, Medical Consulting Czarlewski, Levallois, France, KYomed INNOV, Montpellier, France, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D Unit and Department of Public Health), Naples, Italy, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, Department of ENT, Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd, London, United Kingdom, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden, Department of Geriatrics, Montpellier University Hospital, Montpellier, France, EA 2991, Euromov, University, Montpellier, France, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, Australia, La Rochelle, France, University of Genoa, Department of Internal Medicine, DiMI) and IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Torino, Italy, Région Occitanie, Montpellier, France, Personalized Medicine Clinic Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron and ARADyAL Research Network, Barcelona, Spain, Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, CEDOC-CHRC, Faculdade de Ciências Médicas (FCM), Universidade Nova de Lisboa, Lisbon, Portugal, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Canada, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal, Nîmes, France, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Peercode BV, Geldermalsen, Netherlands, IMT Mines Alès, Université Montpellier, France, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, National Insitute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d'allergologie de l'enfant, Pôle pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland, Department of Clinical Immunology, Wrocław Medical University, Poland, Ukrainina Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Poland, Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), Palermo, Italy, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Department of Social Medicine, Faculty of Medicine, University of Crete, International Primary Care Respiratory Group, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam, Faculty of Health Sciences and CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Allergy Unit 'D Kalogeromitros', 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript, Paraparaumu, New Zealand, Optimum Patient Care, Cambridge, United Kingdom, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Germany and CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit and Smell Clinic, Department of ENT, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia, Department of Immunology, Monash University, Melbourne, Australia, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Department of Allergy, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou,', University of Athens, Athens, Greece, Allergy and Respiratory Diseases, Ospedale Policlino San Martino, University of Genoa, Italy, Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, Santa Maria della Speranza Hospital, Salerno, Italy, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Germany, Department of Allergy, Pasteur Institute, Paris, France, Observational and Pragmatic Research Institute, Singapore, Singapore, Department of Otorhinolaryngology, University of Crete, School of Medicine, Heraklion, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Portugal, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Association Asthme et Allergie, Paris, France, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Faculty of Medicine, Autnonous University of Madrid, Spain, Royal National TNE Hospital, University College London, London, United Kingdom, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Respiratory Medicine, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, European Health Futures Forum (EHFF), Dromahair, Ireland, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of General ORL, H1NS, Medical University of Graz, Graz, Austria, Vilnius University Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, and University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia

Abstract

The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2020

24. Correction to: 'ARIA guideline 2019: treatment of allergic rhinitis in the German health system' (Allergo Journal International, (2019), 28, 7, (255-276), 10.1007/s40629-019-00110-9)

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Abstract

Correction to: Allergo J Int 2019 https://doi.org/10.1007/s40629-019-00110-9 Affiliation and disclaimer have been misrepresented and are hereby corrected: Vera Mahler: Affiliation: Med. Faculty, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany. Disclaimer: The views expressed in this. © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Published
2020

25. The evolving algorithm of biological selection in severe asthma

Author

Papadopoulos, N.G. Barnes, P. Canonica, G.W. Gaga, M. Heaney, L. Menzies-Gow, A. Kritikos, V. Fitzgerald, M.

Abstract

New therapeutic options for severe asthma have recently emerged, mostly in the form of monoclonal antibodies (“biologicals”) targeting relevant inflammatory pathways. Currently available agents target different aspects of “Type 2” immunity, and their indications often include overlapping patient groups. We present a round-table discussion that took place during the Annual Meeting of the Respiratory Effectiveness Group (REG), on the reasoning behind the use of different add-on medications for severe asthma, and crucially, on selection strategies. The proposed rational is based on current evidence, including real-life studies, as well as on the appreciation of the relevant complexities. Direct head-to-head comparisons of biologicals are lacking; therefore, algorithms for initial choice and potential switch between agents should be based on understanding the key characteristics of different options and the development of a clear plan with predefined targets and shared decision-making, in a structured way. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

26. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

Author

Bousquet, J., Farrell, J., Illario, M., Onorato, G.L., Bedbrook, A., Czarlewski, W., Micheli, Y., Arnavielhe, S., Ansotegui, I.J., Anto, J.M., Bachert, C., Basagana, X., Bedard, A., Benveniste, S., Bergmann, K.C., Bewick, M., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bosnic-Anticevich, S., Bosse, I., Braido, F., Brussino, L., Camuzat, T., Canonica, G.W., Cardona, V., Martins, P.C., Cecchi, L., Chavannes, N.H., Chu, D.K., Sousa, J.C. da, Costa, D.J., Costa, E., Cruz, A.A., Silva, J. da, Devillier, P., Feo, G. de, Vries, G. de, Dray, G., Ebisawa, M., Erhola, M., Fauquert, J.L., Fokkens, W.J., Fonseca, J., Fontaine, J.M., Gemicioglu, B., Haahtela, T., Heffler, E., Hellings, P.W., Ivancevich, J.C., Jassem, E., Jutel, M., Kaidashev, I., Kalayci, O., Klimek, L., Kowalski, M.L., Kull, I., Kuna, P., Kvedariene, V., Grutta, S. la, Laune, D., Larenas-Linnemann, D., Ierodiakonou, D., L.T.T. le, Lourenco, O., Makris, M., Menditto, E., Monti, R., Morais-Almeida, M., Munter, L., Muraro, A., Murray, R., Maurer, M., Melen, E., Mosges, R., Mullol, J., Niedoszytko, M., O'Hehir, R.E., Okamoto, Y., Papadopoulos, N.G., Passalacqua, G., Patella, V., Pereira, A.M., Pfaar, O., Pham-Thi, N., Portejoie, F., Price, D., Prokopakis, E.P., Psarros, F., Raciborski, F., Regateiro, F., Reitsma, S., Roche, N., Rolland, C., Ryan, D., Samolinski, B., Sastre, J., Scadding, G.K., Schmid-Grendelmeier, P., Schunemann, H.J., Shamji, M., Sheikh, A., Stellato, C., Suppli-Ulrik, C., Somekh, D., Sova, M., Bom, A.T., Tomazic, P.V., Toppila-Salmi, S., Triggiani, M., Tsiligianni, I., Valero, A., Valiulis, A., Valovirta, E., Eerd, M. van, Vasankari, T., Ventura, M.T., Wallace, D., Waserman, S., Yorgancioglu, A., Zidarn, M., Zuberbier, T., ARIA-MASK Study Grp, Bousquet, J., Farrell, J., Onorato, G. L., Bedbrook, A., Czarlewski, W., Micheli, Y., Arnavielhe, S., Illario, M., Ansotegui, I. J., Anto, J. M., Bachert, C., Basagana, X., Bedard, A., Benveniste, S., Bergmann, K. C., Bewick, M., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bosnic-Anticevich, S., Bosse, I., Braido, F., Brussino, L., Camuzat, T., Canonica, G. W., Cardona, V., Carreiro Martins, P., Cecchi, L., Chavannes, N. H., Chu, D. K., Correia da Sousa, J., Costa, D. J., Costa, E., Cruz, A. A., da Silva, J., Devillier, P., de Feo, G., de Vries, G., Dray, G., Ebisawa, M., Erhola, M., Fauquert, J. L., Fokkens, W. J., Fonseca, J., Fontaine, J. M., Gemicioglu, B., Haahtela, T., Heffler, E., Hellings, P. W., Ivancevich, J. C., Jassem, E., Jutel, M., Kaidashev, I., Kalayci, O., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., la Grutta, S., Laune, D., Larenas-Linnemann, D., Ierodiakonou, D., Le, L. T. T., Lourenco, O., Makris, M., Menditto, E., Monti, R., Morais-Almeida, M., Munter, L., Muraro, A., Murray, R., Maurer, M., Melen, E., Mosges, R., Mullol, J., Niedoszytko, M., O'Hehir, R. E., Okamoto, Y., Papadopoulos, N. G., Passalacqua, G., Patella, V., Pereira, A. M., Pfaar, O., Pham-Thi, N., Portejoie, F., Price, D., Prokopakis, E. P., Psarros, F., Raciborski, F., Regateiro, F., Reitsma, S., Roche, N., Rolland, C., Ryan, D., Samolinski, B., Sastre, J., Scadding, G. K., Schmid-Grendelmeier, P., Schunemann, H. J., Shamji, M., Sheikh, A., Stellato, C., Suppli-Ulrik, C., Somekh, D., Sova, M., Todo Bom, A., Tomazic, P. V., Toppila-Salmi, S., Triggiani, M., Tsiligianni, I., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., Vasankari, T., Ventura, M. T., Wallace, D., Waserman, S., Yorgancioglu, A., Zidarn, M., Zuberbier, T., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Ghent University Hospital, Department of Dermatology and Allergy Center, Odense University Hospital, The University of Sydney, Informatique, Image, Intelligence Artificielle (I3A), Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IMT - MINES ALES (IMT - MINES ALES), and Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)

Subjects
Pulmonary and Respiratory Medicine, Process management, Allergy, IMPACT, Immunology, Mobile application, Review, health, Clinical decision support system, GLOBAL ALLIANCE, Asthma, Health, Healthy aging, Mobile applications, Rhinitis, Financial management, 03 medical and health sciences, [SPI]Engineering Sciences [physics], 0302 clinical medicine, Blueprint, QUALITY-OF-LIFE, HDE ALER, Health care, Medicine and Health Sciences, Immunology and Allergy, Medicine, TECHNOLOGY, 030223 otorhinolaryngology, Total quality management, Science & Technology, ARIA, business.industry, Digital transformation, GENERATION CARE PATHWAYS, ALLERGIC RHINITIS, CHRONIC RESPIRATORY-DISEASES, 030228 respiratory system, General partnership, GA(2)LEN, business, Life Sciences & Biomedicine, ASTHMA MULTIMORBIDITY, Health care quality
Abstract

The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. ispartof: ALLERGY ASTHMA & IMMUNOLOGY RESEARCH vol:12 issue:2 pages:238-258 ispartof: location:Korea (South) status: published

Published
2020

27. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Author

Agache, I. Beltran, J. Akdis, C. Akdis, M. Canelo-Aybar, C. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Hernández-Martín, I. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Posso, M. Rocha, C. Quirce, S. Sastre, J. Shamji, M. Song, Y. Steiner, C. Schwarze, J. Alonso-Coello, P. Palomares, O. Jutel, M.

Abstract

Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using GRADE. 19 RCTs (three RCTs for benralizumab, three RCTs for dupilumab, three RCTs for mepolizumab, five RCTs for omalizumab and five RCTs for reslizumab), including subjects 12 to 75 years old (except for omalizumab including also subjects 6-11 years old), ranging from 12 to 56 weeks were evaluated. All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab incidence rate ratio (IRR) 0.53 (95% CI 0.39 to 0.72), dupilumab (IRR) 0.43 (95% CI 0.32 to 0.59), mepolizumab IRR 0.49 (95% CI 0.38 to 0.66), omalizumab (IRR) 0.56 (95% CI 0.40 to 0.77) and reslizumab (IRR) 0.46 (95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve asthma control, QoL and FEV1, without reaching the minimal important difference (moderate certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug-related adverse events (AE) and drug-related serious AE (low to very low certainty of evidence). The incremental cost-effectiveness ratio per quality-adjusted life year value is above the willingness to pay threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in hospitalizations, emergency and primary care visits. There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is moderate certainty for improving asthma control, QoL, FEV1. More data on long-term safety are needed together with more efficacy data in the paediatric population. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

28. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

Author

Agache, I. Song, Y. Rocha, C. Beltran, J. Posso, M. Steiner, C. Alonso-Coello, P. Akdis, C. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Martín, I.H. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Canelo-Aybar, C. Palomares, O. Jutel, M.

Abstract

Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor α, is approved as add-on maintenance treatment for inadequately controlled type 2 severe asthma. This systematic review evaluated the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled severe asthma. PubMed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. Three RCTs including 2735 subjects >12 years old and 24-52 weeks of follow-up were included. Dupilumab reduced with high certainty severe asthma exacerbations (Incidence rate ratio 0.51; 95% CI 0.45-0.59) and the percentage use of oral corticosteroid use (mean difference (MD) −28.2 mg/d; 95% CI −40.7 to −15.7). Asthma control (ACQ-5), quality of life (AQLQ) and rescue medication use [puffs/d] improved, without reaching the minimal important clinical difference: ACQ-5 MD −0.28 (95% CI −0.39 to −0.17); AQLQ MD +0.28 (95% CI 0.20-0.37); and rescue medication MD −0.35 (95% CI −0.73 to +0.02). FEV1 increased (MD +0.15; 95% CI +0.11 to +0.18) (moderate certainty). There was an increased rate of dupilumab-related adverse events (AEs) (moderate certainty) and of drug-related serious AEs (low certainty). The incremental cost-effectiveness ratio of dupilumab versus standard therapy was 464 000$/QALY (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

29. International severe asthma registry (ISAR): Protocol for a global registry

Author

Fitzgerald, J.M. Tran, T.N. Alacqua, M. Altraja, A. Backer, V. Bjermer, L. Bjornsdottir, U. Bourdin, A. Brusselle, G. Bulathsinhala, L. Busby, J. Canonica, G.W. Carter, V. Chaudhry, I. Cho, Y.S. Christoff, G. Cosio, B.G. Costello, R.W. Eleangovan, N. Gibson, P.G. Heaney, L.G. Heffler, E. Hew, M. Hosseini, N. Iwanaga, T. Jackson, D.J. Jones, R. Koh, M.S. Le, T. Lehtimäki, L. Ludviksdottir, D. Maitland-Van Der Zee, A.H. Menzies-Gow, A. Murray, R.B. Papadopoulos, N.G. Perez-De-Llano, L. Peters, M. Pfeffer, P.E. Popov, T.A. Porsbjerg, C.M. Price, C.A. Rhee, C.K. Sadatsafavi, M. Tohda, Y. Wang, E. Wechsler, M.E. Zangrilli, J. Price, D.B.

Abstract

Background: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour. Methods: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (=18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics and Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders. Conclusions: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally. © 2020 The Author(s).

Published
2020

30. EUFOREA treatment algorithm for allergic rhinitis.

Author

Harvey R., Hellings P.W., Bachert C., Bjermer L., Canonica G.W., Cardell L.O., Carney A.S., Constantinidis J., Deneyer L., Diamant Z., Durham S., Gevaert P., Hopkins C., Kjeldsen A., Klimek L., Lund V.J., Price D., Rimmer J., Ryan D., Roberts G., Sahlstrand-Johnson P., Salmi S., Samji M., Scadding G., Smith P., Steinsvik A., Wagenmann M., Seys S., Wahn U., Fokkens W.J., Harvey R., Hellings P.W., Bachert C., Bjermer L., Canonica G.W., Cardell L.O., Carney A.S., Constantinidis J., Deneyer L., Diamant Z., Durham S., Gevaert P., Hopkins C., Kjeldsen A., Klimek L., Lund V.J., Price D., Rimmer J., Ryan D., Roberts G., Sahlstrand-Johnson P., Salmi S., Samji M., Scadding G., Smith P., Steinsvik A., Wagenmann M., Seys S., Wahn U., and Fokkens W.J.

Published
2020

31. International Severe Asthma Registry Mission Statement

Author

Canonica, G.W., Alacqua, M., Altraja, A., Backer, V., Bel, E., Bjermer, L. (Leif), Price, D. (David), Canonica, G.W., Alacqua, M., Altraja, A., Backer, V., Bel, E., Bjermer, L. (Leif), and Price, D. (David)

Abstract

Regional and/or national severe asthma registries provide valuable country-specific information. However, they are often limited in scope within the broader definitions of severe asthma, have insufficient statistical power to answer many research questions, lack intraoperability to share lessons learned, and have fundamental differences in data collected, making cross comparisons difficult. What is missing is a worldwide registry which brings all severe asthma data together in a cohesive way, under a single umbrella, based on standardized data collection protocols, permitting data to be shared seamlessly. The International Severe Asthma Registry (ISAR; http://isaregistries.org/) is the first global adult severe asthma registry. It is a joint initiative where national registries (both newly created and preexisting) retain ownership of their own data but open their borders and share data with ISAR for ethically approved research purposes. Its strength comes from collection of patient-level, anonymous, longitudinal, reallife, standardized, high-quality data (using a core set of variables) from countries across the

Published
2020
Full Text
View/download PDF

35. PRS62 Applying Multiple Criteria Decision Analysis (MCDA) to Assess the VALUE of Budesonide-Formoterol Maintenance and Reliever Therapy in Asthma- an Empirical Case Study

Author

Aiello, A., primary, Amoroso, C., additional, Berto, P., additional, Canonica, G.W., additional, Cattani, L., additional, Cicchetti, A., additional, Coratella, G., additional, Di Marco, F., additional, Fedriga, A.L., additional, Lombardo, F.P., additional, Maffezzoli, S., additional, Manna, G., additional, Ruggeri, I., additional, Saleri, C., additional, Samaha, D., additional, Trifirò, G., additional, and Ubertazzo, L., additional

Published
2020
Full Text
View/download PDF

36. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Author

Bousquet J., Arnavielhe S., Bedbrook A., Bewick M., Laune D., Mathieu-dupas E., Murray R., Onorato G.L., Pepin J.L., Picard R., Portejoie F., Costa E., Fonseca J., Lourenco O., Morais-Almeida M., Todo-bom A., Cruz A.A., Silva J.D., Serpa F.S., Illario M., Menditto E., Cecchi L., Monti R., Napoli L., Ventura M.T., De Feo G., Larenas-linnemann D., Fuentes Perez M., Huerta Villabolos Y.R., Rivero-yeverino D., Rodriguez-zagal E., Amat F., Annesi-maesano I., Bosse I., Demoly P., Devillier P., Fontaine J.F., Just J., Kuna T.P., Samolinski B., Valiulis A., Emuzyte R., Kvedariene V., Ryan D., Sheikh A., Schmidt-grendelmeier P., Klimek L., Pfaar O., Bergmann K.C., Mosges R., Zuberbier T., Roller-wirnsberger R.E., Tomazic P., Fokkens W.J., Chavannes N.H., Reitsma S., Anto J.M., Cardona V., Dedeu T., Mullol J., Haahtela T., Salimaki J., Toppila-Salmi S., Valovirta E., Gemicioglu B., Yorgancioglu A., Papadopoulos N., Prokopakis E.P., Bosnic-anticevich S., O'hehir R., Ivancevich J.C., Neffen H., Zernotti E., Kull I., Melen E., Wickman M., Bachert C., Hellings P., Palkonen S., Bindslev-jensen C., Eller E., Waserman S., Sova M., De Vries G., van Eerd M., Agache I., Casale T., Dykewickz M., Naclerio R.N., Okamoto Y., Wallace D.V., Hellings P.W., Aberer W., Akdis C.A., Akdis M., Alberti M.R., Almeida R., Angles R., Ansotegui I.J., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Basagana X., Bateman E.D., Bedolla-Barajas M., Beghe B., Bel E.H., Bennoor K.S., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bosnic-Anticevich C.S., Bouchard J., Boulet L.P., Bourret R., Bousquet P.J., Braido F., Briedis V., Brightling C.E., Brozek J., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillot D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Canonica G.W., Carlsen K.H., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Castellano G., Cepeda A.M., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Correia de Sousa J., Cortes-Grimaldo R.M., Corti F., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Czarlewski W., Dahlen S.E., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., De Carlo G., de Fatima Emerson M., De Martino B., de Paula Motta Rubini N., Deleanu D., Denburg J.A., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Dykewicz M.S., El-Gamal Y., Eklund P., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Fonseca J.A., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Aymerich J., Garcia-Cobas C.Y., Garcia-Cruz M.H., Genova S., George C., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Guzman M.A., Hajjam J., Hernandez L., Hourihane J.O.'.B., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Jutel M., Kaidashev I., Kalayci O., Kalyoncu A.F., Karjalainen J., Kardas P., Keil T., Keith P.K., Khaitov M., Khaltaev N., Kleine-Tebbe J., Kowalski M.L., Kuitunen M., Kuna P., Kupczyk M., Krzych-Falta E., Lacwik P., Lauri D., Lavrut J., Le L.T.T., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Luna-Pech J.A., Maciej K., Magnan A., Mahboub B., Maier D., Mair A., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Medina-Avalos M.A., Melo-Gomes E., Meltzer E.O., Mercier J., Miculinic N., Mihaltan F., Milenkovic B., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Mora Bogado D., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Naclerio R., Nadif R., Nalin M., Namazova-Baranova L., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Novellino E., Nyembue T.D., O'hehir R.E., Odzhakova C., Ohta K., Okubo K., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Panzner P., Papadopoulos N.G., Park H.S., Papi A., Passalacqua G., Paulino E., Pawankar R., Pedersen S., Pereira A.M., Persico M., Phillips J., Pigearias B., Pin I., Pitsios C., Plavec D., Pohl W., Popov T.A., Potter P., Pozzi A.C., Price D., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Rajabian-Soderlund R., Ribeirinho I., Rimmer J., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rolla G., Romano M., Rosado-Pinto J., Rosario N., Rottem M., Sagara H., Sanchez-Borges M., Sastre-Dominguez J., Scadding G.K., Schunemann H.J., Scichilone N., Schmid-Grendelmeier P., Shamai S., Sierra M., Simons F.E.R., Siroux V., Sisul J.C., Skrindo I., Sole D., Somekh D., Sondermann M., Sooronbaev T., Sorensen M., Sorlini M., Spranger O., Stellato C., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., To T., Tomazic P.V., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., Valero A., van Ganse E., van Hague M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi G., Vicheva D., Vontetsianos T., Wagenmann M., Walker S., Wallace D., Wang D.Y., Werfel T., Westman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zhang L., Zhong N., Zernotti M.E., Zidarn M., Zubrinich C., Zurkuhlen A., [et al.], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (Sysdiag), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire [Grenoble] (CHU), Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Istituto di Astrofisica Spaziale, Universidade de Lisboa (ULISBOA), University of Beira Interior [Portugal] (UBI), University of Coimbra [Portugal] (UC), 'Federico II' University of Naples Medical School, University of Salerno (UNISA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Montpellier, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Hôpital Foch [Suresnes], Institut d'Electronique du Solide et des Systèmes (InESS), Centre National de la Recherche Scientifique (CNRS), Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Medical University of Warsaw - Poland, Vilnius University [Vilnius], University of Edinburgh, University hospital of Zurich [Zurich], Heidelberg University, University Hospital of Cologne [Cologne], University of Graz, Vall d'Hebron University Hospital [Barcelona], University of Barcelona, University of Helsinki [Helsinki], University of Turku, University of Manchester [Manchester], The University of Sydney [Sydney], Monash University [Melbourne], The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Uppsala University, Ghent University Hospital, University Hospitals Leuven [Leuven], McMaster University [Hamilton, Ontario], Transilvania University of Brasov, University of South Florida (USF), Johns Hopkins University School of Medicine [Baltimore], Institute for Solid State Physics [Tokyo] (ISSP), The University of Tokyo, Department of Oceanography, Dalhousie University [Halifax], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade do Porto, Università degli Studi di Salerno (UNISA), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Allergologie pédiatrique [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Medical University of Łódź (MUL), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Karl-Franzens-Universität [Graz, Autriche], Leiden University Medical Center (LUMC), Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, IMIM-Hospital del Mar, Generalitat de Catalunya, CIBER de Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra [Barcelona] (UPF), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), University of Helsinki, The University of Sydney, University of Amsterdam [Amsterdam] (UvA), University of South Florida [Tampa] (USF), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Kyomed, iQ4U consultants Ltd, MedScript Ltd, Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2 ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Conseil général de l'économie, de l'industrie et des technologies (CGEIET), Ministère de l'Economie, des Finances et de l'Industrie, The University of Tokyo (UTokyo), Federazione Italiana Medici di Medicina Generale (FIMMG), uBibliorum, Bousquet, J., Arnavielhe, S., Bedbrook, A., Bewick, M., Laune, D., Mathieu-Dupas, E., Murray, R., Onorato, G. L., Pépin, J. L., Picard, R., Portejoie, F., Costa, E., Fonseca, J., Lourenço, O., Morais-Almeida, M., Todo-Bom, A., Cruz, A. A., Da Silva, J., Serpa, F. S., Illario, M., Menditto, E., Cecchi, L., Monti, R., Napoli, L., Ventura, M. T., De Feo, G., Larenas-Linnemann, D., Fuentes Perez, M., Huerta Villabolos, Y. R., Rivero-Yeverino, D., Rodriguez-Zagal, E., Amat, F., Annesi-Maesano, I., Bosse, I., Demoly, P., Devillier, P., Fontaine, J. F., Just, J., Kuna, T. P., Samolinski, B., Valiulis, A., Emuzyte, R., Kvedariene, V., Ryan, D., Sheikh, A., Schmidt-Grendelmeier, P., Klimek, L., Pfaar, O., Bergmann, K. C., Mösges, R., Zuberbier, T., Roller-Wirnsberger, R. E., Tomazic, P., Fokkens, W. J., Chavannes, N. H., Reitsma, S., Anto, J. M., Cardona, V., Dedeu, T., Mullol, J., Haahtela, T., Salimäki, J., Toppila-Salmi, S., Valovirta, E., Gemicioǧlu, B., Yorgancioglu, A., Papadopoulos, N., Prokopakis, E. P., Bosnic-Anticevich, S., O'Hehir, R., Ivancevich, J. C., Neffen, H., Zernotti, E., Kull, I., Melen, E., Wickman, M., Bachert, C., Hellings, P., Palkonen, S., Bindslev-Jensen, C., Eller, E., Waserman, S., Sova, M., De Vries, G., Van Eerd, M., Agache, I., Casale, T., Dykewickz, M., Naclerio, R. N., Okamoto, Y., Wallace, D. V., Universidade do Minho, Bousquet J., Arnavielhe S., Bedbrook A., Bewick M., Laune D., Mathieu-dupas E., Murray R., Onorato G.L., Pepin J.L., Picard R., Portejoie F., Costa E., Fonseca J., Lourenco O., Morais-Almeida M., Todo-bom A., Cruz A.A., Silva J.D., Serpa F.S., Illario M., Menditto E., Cecchi L., Monti R., Napoli L., Ventura M.T., De Feo G., Larenas-linnemann D., Fuentes Perez M., Huerta Villabolos Y.R., Rivero-yeverino D., Rodriguez-zagal E., Amat F., Annesi-maesano I., Bosse I., Demoly P., Devillier P., Fontaine J.F., Just J., Kuna T.P., Samolinski B., Valiulis A., Emuzyte R., Kvedariene V., Ryan D., Sheikh A., Schmidt-grendelmeier P., Klimek L., Pfaar O., Bergmann K.C., Mosges R., Zuberbier T., Roller-wirnsberger R.E., Tomazic P., Fokkens W.J., Chavannes N.H., Reitsma S., Anto J.M., Cardona V., Dedeu T., Mullol J., Haahtela T., Salimaki J., Toppila-Salmi S., Valovirta E., Gemicioglu B., Yorgancioglu A., Papadopoulos N., Prokopakis E.P., Bosnic-anticevich S., O'hehir R., Ivancevich J.C., Neffen H., Zernotti E., Kull I., Melen E., Wickman M., Bachert C., Hellings P., Palkonen S., Bindslev-jensen C., Eller E., Waserman S., Sova M., De Vries G., van Eerd M., Agache I., Casale T., Dykewickz M., Naclerio R.N., Okamoto Y., Wallace D.V., Hellings P.W., Aberer W., Akdis C.A., Akdis M., Alberti M.R., Almeida R., Angles R., Ansotegui I.J., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Basagana X., Bateman E.D., Bedolla-Barajas M., Beghe B., Bel E.H., Bennoor K.S., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bosnic-Anticevich C.S., Bouchard J., Boulet L.P., Bourret R., Bousquet P.J., Braido F., Briedis V., Brightling C.E., Brozek J., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillot D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Canonica G.W., Carlsen K.H., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Castellano G., Cepeda A.M., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Correia de Sousa J., Cortes-Grimaldo R.M., Corti F., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Czarlewski W., Dahlen S.E., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., De Carlo G., de Fatima Emerson M., De Martino B., de Paula Motta Rubini N., Deleanu D., Denburg J.A., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Dykewicz M.S., El-Gamal Y., Eklund P., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Fonseca J.A., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Aymerich J., Garcia-Cobas C.Y., Garcia-Cruz M.H., Genova S., George C., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Guzman M.A., Hajjam J., Hernandez L., Hourihane J.O.'.B., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Jutel M., Kaidashev I., Kalayci O., Kalyoncu A.F., Karjalainen J., Kardas P., Keil T., Keith P.K., Khaitov M., Khaltaev N., Kleine-Tebbe J., Kowalski M.L., Kuitunen M., Kuna P., Kupczyk M., Krzych-Falta E., Lacwik P., Lauri D., Lavrut J., Le L.T.T., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Luna-Pech J.A., Maciej K., Magnan A., Mahboub B., Maier D., Mair A., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Medina-Avalos M.A., Melo-Gomes E., Meltzer E.O., Mercier J., Miculinic N., Mihaltan F., Milenkovic B., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Mora Bogado D., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Naclerio R., Nadif R., Nalin M., Namazova-Baranova L., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Novellino E., Nyembue T.D., O'hehir R.E., Odzhakova C., Ohta K., Okubo K., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Panzner P., Papadopoulos N.G., Park H.S., Papi A., Passalacqua G., Paulino E., Pawankar R., Pedersen S., Pereira A.M., Persico M., Phillips J., Pigearias B., Pin I., Pitsios C., Plavec D., Pohl W., Popov T.A., Potter P., Pozzi A.C., Price D., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Rajabian-Soderlund R., Ribeirinho I., Rimmer J., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rolla G., Romano M., Rosado-Pinto J., Rosario N., Rottem M., Sagara H., Sanchez-Borges M., Sastre-Dominguez J., Scadding G.K., Schunemann H.J., Scichilone N., Schmid-Grendelmeier P., Shamai S., Sierra M., Simons F.E.R., Siroux V., Sisul J.C., Skrindo I., Sole D., Somekh D., Sondermann M., Sooronbaev T., Sorensen M., Sorlini M., Spranger O., Stellato C., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., To T., Tomazic P.V., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., Valero A., van Ganse E., van Hague M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi G., Vicheva D., Vontetsianos T., Wagenmann M., Walker S., Wallace D., Wang D.Y., Werfel T., Westman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zhang L., Zhong N., Zernotti M.E., Zidarn M., Zubrinich C., Zurkuhlen A., Internal Medicine, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie

Subjects
Allergy, HEALTH-ORGANIZATION, IMPACT, Respiratory Medicine and Allergy, [SDV]Life Sciences [q-bio], Allergic Rhinitis and its Impact on Asthma - ARIA, Review, MASK - Mobile Airways Sentinel networK, 0302 clinical medicine, 610 Medical sciences Medicine, App, ARIA, Asthma, Care pathways, MASK, mHealth, Rhinitis, Immunology and Allergy, Immunology, Pulmonary and Respiratory Medicine, Health care, Medicine and Health Sciences, 030212 general & internal medicine, Android (operating system), Rinitis, Rhiniti, ComputingMilieux_MISCELLANEOUS, Lungmedicin och allergi, PRODUCTIVITY, 3. Good health, ALLERGIC RHINITIS, Rinite, Medical emergency, Life Sciences & Biomedicine, STRATEGIES, MASK study group, MEDLINE, K-ANONYMITY, Pharmacy, [object Object], Settore MED/10 - Malattie Dell'Apparato Respiratorio, VALIDATION, MACVIA-ARIA, 03 medical and health sciences, medicine, Mobile technology, TECHNOLOGY, App -MASK, Asma, Care pathway, Science & Technology, business.industry, Settore MED/09 - MEDICINA INTERNA, Correction, Guideline, RC581-607, medicine.disease, 030228 respiratory system, Immunologic diseases. Allergy, business, EUROPEAN COUNTRIES, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary., UZ Leuven -Universitaire Ziekenhuizen Leuven, KU Leuven(GA2LEN), info:eu-repo/semantics/publishedVersion

Published
2018

37. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

Author

Bousquet, J. Bedbrook, A. Czarlewski, W. Onorato, G.L. Arnavielhe, S. Laune, D. Mathieu-Dupas, E. Fonseca, J. Costa, E. Lourenço, O. Morais-Almeida, M. Todo-Bom, A. Illario, M. Menditto, E. Canonica, G.W. Cecchi, L. Monti, R. Napoli, L. Ventura, M.T. De Feo, G. Fokkens, W.J. Chavannes, N.H. Reitsma, S. Cruz, A.A. Da Silva, J. Serpa, F.S. Larenas-Linnemann, D. Fuentes Perez, J.M. Huerta-Villalobos, Y.R. Rivero-Yeverino, D. Rodriguez-Zagal, E. Valiulis, A. Dubakiene, R. Emuzyte, R. Kvedariene, V. Annesi-Maesano, I. Blain, H. Bonniaud, P. Bosse, I. Dauvilliers, Y. Devillier, P. Fontaine, J.F. Pépin, J.L. Pham-Thi, N. Portejoie, F. Picard, R. Roche, N. Rolland, C. Schmidt-Grendelmeier, P. Kuna, P. Samolinski, B. Anto, J.M. Cardona, V. Mullol, J. Pinnock, H. Ryan, D. Sheikh, A. Walker, S. Williams, S. Becker, S. Klimek, L. Pfaar, O. Bergmann, K.C. Mösges, R. Zuberbier, T. Roller-Wirnsberger, R.E. Tomazic, P.V. Haahtela, T. Salimäki, J. Toppila-Salmi, S. Valovirta, E. Vasankari, T. Gemicioǧlu, B. Yorgancioglu, A. Papadopoulos, N.G. Prokopakis, E.P. Tsiligianni, I.G. Bosnic-Anticevich, S. O'Hehir, R. Ivancevich, J.C. Neffen, H. Zernotti, M.E. Kull, I. Melén, E. Wickman, M. Bachert, C. Hellings, P.W. Brusselle, G. Palkonen, S. Bindslev-Jensen, C. Eller, E. Waserman, S. Boulet, L.P. Bouchard, J. Chu, D.K. Schünemann, H.J. Sova, M. De Vries, G. Van Eerd, M. Agache, I. Ansotegui, I.J. Bewick, M. Casale, T. Dykewick, M. Ebisawa, M. Murray, R. Naclerio, R. Okamoto, Y. Wallace, D.V. Aberer, W. Akdis, C.A. Akdis, M. Aliberti, M.R. Almeida, R. Amat, F. Angles, R. Arnavielle, S. Asayag, E. Asarnoj, A. Arshad, H. Avolio, F. Bacci, E. Baiardini, I. Barbara, C. Barbagallo, M. Baroni, I. Barreto, B.A. Basagana, X. Bateman, E.D. Bedolla-Barajas, M. Beghé, B. Bel, E.H. Bennoor, K.S. Benson, M. Bertorello, L. Białoszewski, A.Z. Bieber, T. Bialek, S. Bjermer, L. Blasi, F. Blua, A. Bochenska Marciniak, M. Bogus-Buczynska, I. Boner, A.L. Bonini, M. Bonini, S. Bourret, R. Braido, F. Briedis, V. Brightling, C.E. Brozek, J. Bucca, C. Buhl, R. Buonaiuto, R. Panaitescu, C. Burguete Cabañas, M.T. Burte, E. Bush, A. Caballero-Fonseca, F. Caillaud, D. Caimmi, D. Calderon, M.A. Camargos, P.A.M. Camuzat, T. Canfora, G. Carlsen, K.H. Carreiro-Martins, P. Carriazo, A.M. Carr, W. Cartier, C. Castellano, G. Cepeda, A.M. Chen, Y. Chiron, R. Chivato, T. Chkhartishvili, E. Chuchalin, A.G. Chung, K.F. Ciaravolo, M.M. Ciceran, A. Cingi, C. Ciprandi, G. Carvalho Coehlo, A.C. Colas, L. Colgan, E. Coll, J. Conforti, D. De Sousa, J.C. Cortés-Grimaldo, R.M. Corti, F. Costa-Dominguez, M.C. Courbis, A.L. Cox, L. Crescenzo, M. Custovic, A. Dahlen, S.E. D'Amato, G. Dario, C. Darsow, U. De Blay, F. De Carlo, G. Dedeu, T. De Fátima Emerson, M. De Martino, B. Motta Rubina, N.P. Deleanu, D. Demoly, P. Denburg, J.A. Di Capua Ercolano, S. Di Carluccio, N. Didier, A. Dokic, D. Dominguez-Silva, M.G. Douagui, H. Dray, G. Durham, S.R. Du Toit, G. Dykewicz, M.S. El-Gamal, Y. Eklund, P. Farrell, J. Farsi, A. Ferreira De Mello, J., Jr. Ferrero, J. Fink-Wagner, A. Fiocchi, A. Forti, S. Fuentes-Perez, J.M. Gálvez-Romero, J.L. Gamkrelidze, A. Garcia-Aymerich, J. García-Cobas, C.Y. Garcia-Cruz, M.H. Genova, S. Christoff, G. Gereda, J.E. Gerth Van Wijk, R. Gomez, R.M. Gómez-Vera, J. González Diaz, S. Gotua, M. Grisle, I. Guidacci, M. Guldemond, N.A. Gutter, Z. Guzmán, M.A. Hajjam, J. Hernández, L. Hourihane, J.O.B. Humbert, M. Iaccarino, G. Ispayeva, Z. Jares, E.J. Jassem, E. Johnston, S.L. Joos, G. Jung, K.S. Just, J. Jutel, M. Kaidashev, I. Kalayci, O. Kalyoncu, A.F. Karjalainen, J. Kardas, P. Keil, T. Keith, P.K. Khaitov, M. Khaltaev, N. Kleine-Tebbe, J. Kowalski, M.L. Kuitunen, M. Kupczyk, M. Krzych-Fałta, E. Lacwik, P. Lauri, D. Lavrut, J. Le, L.T.T. Lessa, M. Levato, G. Li, J. Lieberman, P. Lipiec, A. Lipworth, B. Lodrup Carlsen, K.C. Louis, R. Luna-Pech, J.A. Magnan, A. Mahboub, B. Maier, D. Mair, A. Majer, I. Malva, J. Mandajieva, E. Manning, P. De Manuel Keenoy, E. Marshall, G.D. Masjedi, M.R. Maspero, J.F. Matta Campos, J.J. Matos, A.L. Maurer, M. Mavale-Manuel, S. Mayora, O. Medina-Avalos, M.A. Melo-Gomes, E. Meltzer, E.O. Mercier, J. Miculinic, N. Mihaltan, F. Milenkovic, B. Moda, G. Mogica-Martinez, M.D. Mohammad, Y. Momas, I. Montefort, S. Mora Bogado, D. Morato-Castro, F.F. Mota-Pinto, A. Moura Santo, P. Münter, L. Muraro, A. Nadif, R. Nalin, M. Namazova-Baranova, L. Niedeberger, V. Nekam, K. Neou, A. Nieto, A. Nogueira-Silva, L. Nogues, M. Novellino, E. Nyembue, T.D. Odzhakova, C. Ohta, K. Okubo, K. Ortega Cisneros, M. Ouedraogo, S. Pali-Schöll, I. Panzner, P. Park, H.S. Papi, A. Passalacqua, G. Paulino, E. Pawankar, R. Pedersen, S. Pereira, A.M. Persico, M. Phillips, J. Pigearias, B. Pin, I. Pitsios, C. Plavec, D. Pohl, W. Popov, T.A. Potter, P. Pozzi, A.C. Price, D. Puy, R. Pugin, B. Pulido Ross, R.E. Przemecka, M. Rabe, K.F. Raciborski, F. Rajabian-Soderlund, R. Ribeirinho, I. Rimmer, J. Rizzo, J.A. Rizzo, M.C. Robalo-Cordeiro, C. Rodenas, F. Rodo, X. Rodriguez Gonzalez, M. Rodriguez-Mañas, L. Rodrigues Valle, S. Roman Rodriguez, M. Romano, A. Rolla, G. Romano, M. Rosado-Pinto, J. Rosario, N. Rottem, M. Sagara, H. Sanchez-Borges, M. Sastre-Dominguez, J. Scadding, G.K. Schunemann, H.J. Scichilone, N. Schmid-Grendelmeier, P. Shamai, S. Simons, F.E.R. Siroux, V. Sisul, J.C. Skrindo, I. Solé, D. Somekh, D. Sondermann, M. Sooronbaev, T. Sorensen, M. Sorlini, M. Spranger, O. Stellato, C. Stelmach, R. Stukas, R. Sunyer, J. Strozek, J. Szylling, A. Tebyriçá, J.N. Thibaudon, M. To, T. Trama, U. Triggiani, M. Suppli Ulrik, C. Urrutia-Pereira, M. Valenta, R. Valero, A. Van Ganse, E. Van Hague, M. Vandenplas, O. Vezzani, G. Vatrella, A. Verissimo, M.T. Viart, F. Viegi, G. Vicheva, D. Vontetsianos, T. Wagenmann, M. Wang, D.Y. Werfel, T. Westman, M. Williams, D.M. Wilson, N. Wright, J. Wroczynski, P. Yakovliev, P. Yawn, B.P. Yiallouros, P.K. Yusuf, O.M. Zar, H.J. Zhang, L. Zhong, N. Zhanat, I. Zidarn, M. Zubrinich, C. Zurkuhlen, A.

Abstract

Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases. © 2019 The Author(s).

Published
2019

38. 2019 ARIA Care pathways for allergen immunotherapy

Author

Bousquet, J. Pfaar, O. Togias, A. Schünemann, H.J. Ansotegui, I. Papadopoulos, N.G. Tsiligianni, I. Agache, I. Anto, J.M. Bachert, C. Bedbrook, A. Bergmann, K.-C. Bosnic-Anticevich, S. Bosse, I. Brozek, J. Calderon, M.A. Canonica, G.W. Caraballo, L. Cardona, V. Casale, T. Cecchi, L. Chu, D. Costa, E. Cruz, A.A. Czarlewski, W. Durham, S.R. Du Toit, G. Dykewicz, M. Ebisawa, M. Fauquert, J.L. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J. Fontaine, J.-F. Gerth van Wijk, R. Haahtela, T. Halken, S. Hellings, P.W. Ierodiakonou, D. Iinuma, T. Ivancevich, J.C. Jacobsen, L. Jutel, M. Kaidashev, I. Khaitov, M. Kalayci, O. Kleine Tebbe, J. Klimek, L. Kowalski, M.L. Kuna, P. Kvedariene, V. La Grutta, S. Larenas-Linemann, D. Lau, S. Laune, D. Le, L. Lodrup Carlsen, K. Lourenço, O. Malling, H.-J. Marien, G. Menditto, E. Mercier, G. Mullol, J. Muraro, A. O’Hehir, R. Okamoto, Y. Pajno, G.B. Park, H.-S. Panzner, P. Passalacqua, G. Pham-Thi, N. Roberts, G. Pawankar, R. Rolland, C. Rosario, N. Ryan, D. Samolinski, B. Sanchez-Borges, M. Scadding, G. Shamji, M.H. Sheikh, A. Sturm, G.J. Todo Bom, A. Toppila-Salmi, S. Valentin-Rostan, M. Valiulis, A. Valovirta, E. Ventura, M.-T. Wahn, U. Walker, S. Wallace, D. Waserman, S. Yorgancioglu, A. Zuberbier, T. the ARIA Working Group

Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2019

39. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

Author

Bulathsinhala, L. Eleangovan, N. Heaney, L.G. Menzies-Gow, A. Gibson, P.G. Peters, M. Hew, M. van Boven, J.F.M. Lehtimäki, L. van Ganse, E. Belhassen, M. Harvey, E.S. Perez de Llano, L. Maitland-van der Zee, A.H. Papadopoulos, N.G. FitzGerald, J.M. Porsbjerg, C. Canonica, G.W. Backer, V. Rhee, C.K. Verhamme, K.M.C. Buhl, R. Cosio, B.G. Carter, V. Price, C. Le, T. Stagno d'Alcontres, M. Gopalan, G. Tran, T.N. Price, D.

Subjects
education
Abstract

Background: The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardized data collection, subsequently enabling data interoperability. Objectives: To create a standardized list of variables for the first international registry for severe asthma via expert consensus. Methods: A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process consisted of 3 iterative rounds. In each round, all Delphi panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi administrator to all panel members at subsequent rounds. Finalization of the core variable list was facilitated by 2 face-to-face meetings. Results: Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen variables will allow severe asthma to be assessed against patient demographics and medical history, patient-reported outcomes, diagnostic information, and clinical characteristics. Physician-reported outcomes such as nonadherence and information about treatment and management strategies will also be recorded. Conclusions: This is the first global attempt to generate an ISAR using a common set of core variables to ensure that data collected across all participating countries are standardized. © 2018 American Academy of Allergy, Asthma & Immunology

Published
2019

40. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 2)

Author

Bousquet, J. Pham-Thi, N. Bedbrook, A. Agache, I. Annesi-Maesano, I. Ansotegui, I. Anto, J.M. Bachert, C. Benveniste, S. Bewick, M. Billo, N. Bosnic-Anticevich, S. Bosse, I. Brusselle, G. Calderon, M.A. Canonica, G.W. Caraballo, L. Cardona, V. Carriazo, A.M. Cash, E. Cecchi, L. Chu, D.K. Colgan, E. Costa, E. Cruz, A.A. Czarlewski, W. Durham, S. Ebisawa, M. Erhola, M. Fauquert, J.-L. Fokkens, W.J. Fonseca, J.A. Guldemond, N. Iinuma, T. Illario, M. Klimek, L. Kuna, P. Kvedariene, V. Larenas-Linneman, D. Laune, D. Le, L.T.T. Lourenço, O. Malva, J.O. Marien, G. Menditto, E. Mullol, J. Münter, L. Okamoto, Y. Onorato, G.L. Papadopoulos, N.G. Perala, M. Pfaar, O. Phillips, A. Phillips, J. Pinnock, H. Portejoie, F. Quinones-Delgado, P. Rolland, C. Rodts, U. Samolinski, B. Sanchez-Borges, M. Schünemann, H.J. Shamji, M. Somekh, D. Togias, A. Toppila-Salmi, S. Tsiligianni, I. Usmani, O. Walker, S. Wallace, D. Valiulis, A. Van der Kleij, R. Ventura, M.T. Williams, S. Yorgancioglu, A. Zuberbier, T.

Published
2019

41. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

Author

Bosnic-Anticevich, S. and Costa, E. and Menditto, E. and Lourenço, O. and Novellino, E. and Bialek, S. and Briedis, V. and Buonaiuto, R. and Chrystyn, H. and Cvetkovski, B. and Di Capua, S. and Kritikos, V. and Mair, A. and Orlando, V. and Paulino, E. and Salimäki, J. and Söderlund, R. and Tan, R. and Williams, D.M. and Wroczynski, P. and Agache, I. and Ansotegui, I.J. and Anto, J.M. and Bedbrook, A. and Bachert, C. and Bewick, M. and Bindslev-Jensen, C. and Brozek, J.L. and Canonica, G.W. and Cardona, V. and Carr, W. and Casale, T.B. and Chavannes, N.H. and Correia de Sousa, J. and Cruz, A.A. and Czarlewski, W. and De Carlo, G. and Demoly, P. and Devillier, P. and Dykewicz, M.S. and Gaga, M. and El-Gamal, Y. and Fonseca, J. and Fokkens, W.J. and Guzmán, M.A. and Haahtela, T. and Hellings, P.W. and Illario, M. and Ivancevich, J.C. and Just, J. and Kaidashev, I. and Khaitov, M. and Khaltaev, N. and Keil, T. and Klimek, L. and Kowalski, M.L. and Kuna, P. and Kvedariene, V. and Larenas-Linnemann, D.E. and Laune, D. and Le, L.T.T. and Lodrup Carlsen, K.C. and Mahboub, B. and Maier, D. and Malva, J. and Manning, P.J. and Morais-Almeida, M. and Mösges, R. and Mullol, J. and Münter, L. and Murray, R. and Naclerio, R. and Namazova-Baranova, L. and Nekam, K. and Nyembue, T.D. and Okubo, K. and O'Hehir, R.E. and Ohta, K. and Okamoto, Y. and Onorato, G.L. and Palkonen, S. and Panzner, P. and Papadopoulos, N.G. and Park, H.-S. and Pawankar, R. and Pfaar, O. and Phillips, J. and Plavec, D. and Popov, T.A. and Potter, P.C. and Prokopakis, E.P. and Roller-Wirnsberger, R.E. and Rottem, M. and Ryan, D. and Samolinski, B. and Sanchez-Borges, M. and Schunemann, H.J. and Sheikh, A. and Sisul, J.C. and Somekh, D. and Stellato, C. and To, T. and Todo-Bom, A.M. and Tomazic, P.V. and Toppila-Salmi, S. and Valero, A. and Valiulis, A. and Valovirta, E. and Ventura, M.T. and Wagenmann, M. and Wallace, D. and Waserman, S. and Wickman, M. and Yiallouros, P.K. and Yorgancioglu, A. and Yusuf, O.M. and Zar, H.J. and Zernotti, M.E. and Zhang, L. and Zidarn, M. and Zuberbier, T. and Bousquet, J., Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, UCIBIO, REQUIMTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, CIRFF, Federico II University, Naples, Italy, Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Department of Pharmacy of University of Naples Federico II, Naples, Italy, Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Department of Clinical Pharmacy of Lithuanian, University of Health Sciences, Kaunas, Lithuania, Pharmacist, Municipality Pharmacy, Sarno, Italy, RiRL, Oakington, Cambridge, United Kingdom, Farmacie Dei Golfi Group, Massa Lubrense, Italy, DG for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Farmacias Holon, Lisbon, Portugal, Association of Finnish Pharmacies, Helsinki, Finland, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, Transylvania University Brasov, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, MACVIA-France, Fondation Partenariale FMC VIA-LR, Montpellier, France, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, iQ4U Consultants Ltd, London, United Kingdom, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Personalized Medicine Clinic Asthma & Allergy, Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall ‘dHebron & ARADyAL Research Network, Barcelona, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, WHO GARD Planning Group, Brasilia, Brazil, Medical Consulting Czarlewski, Levallois, France, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, Medical School Saint Antoine, INSERM and UPMC Sorbonne Université, Paris, France, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Université Paris Saclay, Saclay, France, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, ERS President 2017-2018, Athens Chest Hospital, 7th Resp Med Department and Asthma Center, Athens, Greece, Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, MEDIDA, Lda, Porto, Portugal, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, University of Helsinki, Helsinki, Finland, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation, GARD Chairman, Geneva, Switzerland, Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Biomax Informatics AG, Munich, Germany, Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, MedScript Ltd, Dundalk, Co Louth, Ireland, Johns Hopkins School of Medicine, Baltimore, MD, United States, Scientific Centre of Children's Health under the MoH, Russia, Russian National Research Medical University named Pirogov, Moscow, Russian Federation, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, ENT Department, University Hospital of Kinshasa, Kinshasa, Congo, Department of Otolaryngology, Nippon Medical School, Tokyo, Japan, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, National Hospital Organization Tokyo National Hospital, Tokyo, Japan, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Department of Pediatrics, Nippon Medical School, Tokyo, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Section for Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Centre for Empowering Patients and Communities, Faulkland, Somerset, United Kingdom, Children's Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, University Hospital ‘Sv Ivan Rilski’', Sofia, Bulgaria, Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Past President SLAAI, FACAAI, Edinburgh, United Kingdom, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Médico-Docente la Trinidad, Caracas, Trinidad, Trinidad and Tobago, Clínica El Avila, Altamira, Caracas, Venezuela, The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Sociedad Paraguaya de Alergia Asma e Inmunologie, Asuncion, Paraguay, European Health Futures Forum (EHFF), Isle of Wright, United Kingdom, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Clinic of Children's Diseases and Institute of Health Sciences, Department of Public Health, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Cyprus International Institute for Environmenta & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital 'Archbishop Makarios III', Nicosia, Cyprus, Department of Pulmonology, Celal Bayar University, Manisa, Turkey, The Allergy and Asthma Institute, Islamabad, Pakistan, Department of Paediatrics and Child Health, Red Cross Children's, Hospital, and MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing Institute of Otolaryngology, Beijing, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Comprehensive Allergy Center, A member of GA2LEN, Berlin, Germany, University Hospital, Montpellier, France, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, and Euforea, Brussels, Belgium

Subjects
humanities
Abstract

Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care. © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2019

42. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

Author

Bosnic-Anticevich, S. Costa, E. Menditto, E. Lourenço, O. Novellino, E. Bialek, S. Briedis, V. Buonaiuto, R. Chrystyn, H. Cvetkovski, B. Di Capua, S. Kritikos, V. Mair, A. Orlando, V. Paulino, E. Salimäki, J. Söderlund, R. Tan, R. Williams, D.M. Wroczynski, P. Agache, I. Ansotegui, I.J. Anto, J.M. Bedbrook, A. Bachert, C. Bewick, M. Bindslev-Jensen, C. Brozek, J.L. Canonica, G.W. Cardona, V. Carr, W. Casale, T.B. Chavannes, N.H. Correia de Sousa, J. Cruz, A.A. Czarlewski, W. De Carlo, G. Demoly, P. Devillier, P. Dykewicz, M.S. Gaga, M. El-Gamal, Y. Fonseca, J. Fokkens, W.J. Guzmán, M.A. Haahtela, T. Hellings, P.W. Illario, M. Ivancevich, J.C. Just, J. Kaidashev, I. Khaitov, M. Khaltaev, N. Keil, T. Klimek, L. Kowalski, M.L. Kuna, P. Kvedariene, V. Larenas-Linnemann, D.E. Laune, D. Le, L.T.T. Lodrup Carlsen, K.C. Mahboub, B. Maier, D. Malva, J. Manning, P.J. Morais-Almeida, M. Mösges, R. Mullol, J. Münter, L. Murray, R. Naclerio, R. Namazova-Baranova, L. Nekam, K. Nyembue, T.D. Okubo, K. O'Hehir, R.E. Ohta, K. Okamoto, Y. Onorato, G.L. Palkonen, S. Panzner, P. Papadopoulos, N.G. Park, H.-S. Pawankar, R. Pfaar, O. Phillips, J. Plavec, D. Popov, T.A. Potter, P.C. Prokopakis, E.P. Roller-Wirnsberger, R.E. Rottem, M. Ryan, D. Samolinski, B. Sanchez-Borges, M. Schunemann, H.J. Sheikh, A. Sisul, J.C. Somekh, D. Stellato, C. To, T. Todo-Bom, A.M. Tomazic, P.V. Toppila-Salmi, S. Valero, A. Valiulis, A. Valovirta, E. Ventura, M.T. Wagenmann, M. Wallace, D. Waserman, S. Wickman, M. Yiallouros, P.K. Yorgancioglu, A. Yusuf, O.M. Zar, H.J. Zernotti, M.E. Zhang, L. Zidarn, M. Zuberbier, T. Bousquet, J.

Subjects
humanities
Abstract

Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care. © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2019

43. The importance of real-life research in respiratory medicine: Manifesto of the Respiratory Effectiveness Group

Author

Roche, N. Anzueto, A. Anticevich, S.B. Kaplan, A. Miravitlles, M. Ryan, D. Soriano, J.B. Usmani, O. Papadopoulos, N.G. Canonica, G.W. Agache, I. Barnes, P. Bateman, E. Behr, J. Bjermer, L. Blakey, J. Bouros, D. Bousquet, J. Brown, K. Brusselle, G. Calderon, M. Campbell, J. Cardell, L.O. Castro-Rodriguez, J.A. Chaudhuri, N. Chavannes, N. Corte, T. Costello, R. Cottin, V. Custovic, A. Dandurand, R. Diamant, Z. Demoly, P. Ducharme, F. Feleszko, W. Fitzgerald, M. Fokkens, W. Freeman, D. Gaga, M. Geiser, T. Glaspole, I. Gouder, C. Haughney, J. Heaney, L. Hedlin, G. Hellings, P. Hoe, T.O. Israel, E. Jartti, T. Jones, M. Jones, R. Josephs, L. Kalayci, O. Keane, M. Kocks, J. Lemanske, R. Magnussen, H. Makela, M. Mazzei, M. Matricardi, P. McIvor, A. Molina, M. Morais-Almeida, M. Morell, F. Mosges, R. Mullol, J. Murray, C. Nathan, S. Navarrete, B.A. Pappi, A. Paton, J.Y. Phipatanakul, W. Price, D. Quint, J. Rhee, C.K. Ortega, P.R. Roberts, G. Sadatsafavi, M. Sastre, J. Scadding, G. Selman, M. Singh, D. Sliwinski, P. Small, I. Smith, P. Thomas, M. Tsiligianni, I. van Aalderen, W. van Bowen, J. van den Berge, M. van Ganse, E. Vetsbo, J. Vogelmeier, C. Walsh, S. Xepapadaki, V. Zar, H. the Respiratory Effectiveness Group Collaborators

Published
2019

44. 2019 ARIA Care pathways for allergen immunotherapy [ARIA-Versorgungspfade für die Allergenimmuntherapie 2019]

Author

Bousquet, J. Pfaar, O. Togias, A. Schünemann, H.J. Ansotegui, I. Papadopoulos, N.G. Tsiligianni, I. Agache, I. Anto, J.M. Bachert, C. Bedbrook, A. Bergmann, K.C. Bosnic-Anticevich, S. Bosse, I. Brozek, J. Calderon, M. Canonica, G.W. Caraballo, L. Cardona, V. Casale, T. Cecchi, L. Chu, D.K. Costa, E. Cruz, A.A. Czarlewski, W. Durham, S.R. Du Toit, G. Dykewicz, M. Ebisawa, M. Fauquert, J.L. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J. Fontaine, J.F. Gerth Van Wijk, R. Haahtela, T. Halken, S. Hellings, P.W. Ierodiakonou, D. Iinuma, T. Ivancevich, J.C. Jacobsen, L. Jutel, M. Kaidashev, I. Khaitov, M. Kalayci, O. Kleine Tebbe, J. Klimek, L. Kowalski, M.L. Kuna, P. Kvedariene, V. La Grutta, S. Larenas-Linemann, D. Lau, S. Laune, D. Le, L. Lodrup Carlsen, K. Lourenço, O. Malling, H.J. Marien, G. Menditto, E. Mercier, G. Mullol, J. Muraro, A. O'Hehir, R. Okamoto, Y. Pajno, G.B. Park, H.S. Panzner, P. Passalacqua, G. Pham-Thi, N. Roberts, G. Rolland, C. Rosario, N. Ryan, D. Samolinski, B. Sanchez-Borges, M. Scadding, G. Shamji, M.H. Sheikh, A. Sturm, G.J. Todo Bom, A. Toppila-Salmi, S. Valentin-Rostan, M. Valiulis, A. Valovirta, E. Ventura, M.T. Wahn, U. Walker, S. Wallace, D. Waserman, S. Yorgancioglu, A. Zuberbier, T. ARIA-Arbeitsgruppe

Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. © 2019 Dustri-Verlag Dr. Karl Feistle. All rights reserved.

Published
2019

45. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

Author

Bousquet, J.J. and Schünemann, H.J. and Togias, A. and Erhola, M. and Hellings, P.W. and Zuberbier, T. and Agache, I. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Becker, S. and Bedolla-Barajas, M. and Bewick, M. and Bosnic-Anticevich, S. and Bosse, I. and Boulet, L.P. and Bourrez, J.M. and Brusselle, G. and Chavannes, N. and Costa, E. and Cruz, A.A. and Czarlewski, W. and Fokkens, W.J. and Fonseca, J.A. and Gaga, M. and Haahtela, T. and Illario, M. and Klimek, L. and Kuna, P. and Kvedariene, V. and Le, L.T.T. and Larenas-Linnemann, D. and Laune, D. and Lourenço, O.M. and Menditto, E. and Mullol, J. and Okamoto, Y. and Papadopoulos, N. and Pham-Thi, N. and Picard, R. and Pinnock, H. and Roche, N. and Roller-Wirnsberger, R.E. and Rolland, C. and Samolinski, B. and Sheikh, A. and Toppila-Salmi, S. and Tsiligianni, I. and Valiulis, A. and Valovirta, E. and Vasankari, T. and Ventura, M.-T. and Walker, S. and Williams, S. and Akdis, C.A. and Annesi-Maesano, I. and Arnavielhe, S. and Basagana, X. and Bateman, E. and Bedbrook, A. and Bennoor, K.S. and Benveniste, S. and Bergmann, K.C. and Bialek, S. and Billo, N. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bonini, M. and Bonniaud, P. and Bouchard, J. and Briedis, V. and Brightling, C.E. and Brozek, J. and Buhl, R. and Buonaiuto, R. and Canonica, G.W. and Cardona, V. and Carriazo, A.M. and Carr, W. and Cartier, C. and Casale, T. and Cecchi, L. and Cepeda Sarabia, A.M. and Chkhartishvili, E. and Chu, D.K. and Cingi, C. and Colgan, E. and De Sousa, J.C. and Courbis, A.L. and Custovic, A. and Cvetkosvki, B. and Damato, G. and Da Silva, J. and Dantas, C. and Dokic, D. and Dauvilliers, Y. and Dedeu, A. and De Feo, G. and Devillier, P. and Di Capua, S. and Dykewickz, M. and Dubakiene, R. and Ebisawa, M. and El-Gamal, Y. and Eller, E. and Emuzyte, R. and Farrell, J. and Fink-Wagner, A. and Fiocchi, A. and Fontaine, J.F. and Gemicioǧlu, B. and Schmid-Grendelmeir, P. and Gamkrelidze, A. and Garcia-Aymerich, J. and Gomez, M. and Diaz, S.G. and Gotua, M. and Guldemond, N.A. and Guzmán, M.-A. and Hajjam, J. and O'Hourihane, J.B. and Humbert, M. and Iaccarino, G. and Ierodiakonou, D. and Ivancevich, J.C. and Joos, G. and Jung, K.-S. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Kardas, P. and Keil, T. and Khaitov, M. and Khaltaev, N. and Kleine-Tebbe, J. and Kowalski, M.L. and Kritikos, V. and Kull, I. and Leonardini, L. and Lieberman, P. and Lipworth, B. and Lodrup Carlsen, K.C. and Loureiro, C.C. and Louis, R. and Mair, A. and Marien, G. and Mahboub, B. and Malva, J. and Manning, P. and De Manuel Keenoy, E. and Marshall, G.D. and Masjedi, M.R. and Maspero, J.F. and Mathieu-Dupas, E. and Matricardi, P.M. and Melén, E. and Melo-Gomes, E. and Meltzer, E.O. and Mercier, J. and Miculinic, N. and Mihaltan, F. and Milenkovic, B. and Moda, G. and Mogica-Martinez, M.-D. and Mohammad, Y. and Montefort, S. and Monti, R. and Morais-Almeida, M. and Mösges, R. and Münter, L. and Muraro, A. and Murray, R. and Naclerio, R. and Napoli, L. and Namazova-Baranova, L. and Neffen, H. and Nekam, K. and Neou, A. and Novellino, E. and Nyembue, D. and O'Hehir, R. and Ohta, K. and Okubo, K. and Onorato, G. and Ouedraogo, S. and Pali-Schöll, I. and Palkonen, S. and Panzner, P. and Park, H.-S. and Pépin, J.-L. and Pereira, A.-M. and Pfaar, O. and Paulino, E. and Phillips, J. and Plavec, D. and Popov, T.A. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Pugin, B. and Raciborski, F. and Rajabian-Söderlund, R. and Reitsma, S. and Rodo, X. and Romano, A. and Rosario, N. and Rottem, M. and Ryan, D. and Salimäki, J. and Sanchez-Borges, M.M. and Sisul, J.-C. and Solé, D. and Somekh, D. and Sooronbaev, T. and Sova, M. and Spranger, O. and Stellato, C. and Stelmach, R. and Ulrik, C.S. and Thibaudon, M. and To, T. and Todo-Bom, A. and Tomazic, P.V. and Valero, A.A. and Valenta, R. and Valentin-Rostan, M. and Van Der Kleij, R. and Vandenplas, O. and Vezzani, G. and Viart, F. and Viegi, G. and Wallace, D. and Wagenmann, M. and Wang, D.Y. and Waserman, S. and Wickman, M. and Williams, D.M. and Wong, G. and Wroczynski, P. and Yiallouros, P.K. and Yorgancioglu, A. and Yusuf, O.M. and Zar, H.J. and Zeng, S. and Zernotti, M. and Zhang, L. and Zhong, N.S. and Zidarn, M., MACVIA-France, Fondation Partenariale FMC VIA-LR, CHU, Montpellier Cedex 5, 34295, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny Le Bretonneux, France, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Humboldt-Uniersität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Comprehensive Allergy-Centre, Berlin Institute of Health, Berlin, Germany, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States, National Institute for Health and Welfare, Helsinki, Finland, Dept. of Otorhinolaryngology, Univ Hospitals Leuven, Louvain, Belgium, Academic Medical Center, Univ of Amsterdam, Amsterdam, Netherlands, Faculty of Medicine, Transylvania University, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, Dept. of Otolaryngology, Head and Neck Surgery, University of Mainz, Mainz, Germany, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, iQ4U Consultants Ltd., London, United Kingdom, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, Woolcock Emphysema Centre, Sydney, Australia, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada, EIT Health France, Paris, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, UCIBIO, REQUINTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Levallois, France, Department of Otorhino-Laryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Portugal, Athens Chest Hospital, 7th Resp. Med. Dept. and Asthma Center, Athens, Greece, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Łódź, Poland, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, CIRFF, Federico II University, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital P and A Kyriakou, University of Athens, Athens, Greece, Allergy Department, Pasteur Institute, Paris, France, Conseil General de l'Economie Ministere de l'Economie, de l'Industrie et du Numerique, Paris, France, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Association Asthme et Allergie, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius University, Faculty of Medicine, Vilnius, Lithuania, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, Unit of Geriatric Immunoallergol-ogy, University of Bari Medical School, Bari, Italy, Asthma UK, Mansell Street, London, United Kingdom, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, Department of Medicine, University of Cape Town, Cape Town, South Africa, Dept. of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy, Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Global Alliance Against Chronic Respiratory Diseases (WHO GARD), Joensuu, Finland, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Termofscher Scientific, Uppsala, Sweden, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Department of Geriatrics, Montpellier University hospital, Montpellier, France, EA 2991 Euromov, University Montpellier, Montpellier, France, UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London, United Kingdom, CHU, Dijon, France, Clinical Medicine, Laval's University, Quebec City, Canada, Medicine Department, Hôpital de la Malbaie, Quebec city, QC, Canada, Department of Clinical Pharmacy of Lithuanian, University of Health, Kaunas, Lithuania, Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, United Kingdom, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, Municipality Pharmacy, Sarno, Italy, Personalized Medicine Clinic Asthma and Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalu-sia, Seville, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, ASA-Advanced Solutions Accelerator, Clapiers, France, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia, SLaai, Sociedad Lati-noamericana de Allergia, Asma e Immunologia, Barranquilla, Colombia, Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia, Medical Faculty, ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, United Kingdom, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, PT Government Associate Laboratory, ICVS/3B's, Braga/Guimarães, Portugal, Ecole des Mines, Alès, France, Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom, Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital A. Cardarelli, Naples, Italy, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Cáritas Diocesana de Coimbra, Coimbra, Portugal, Ageing at Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Medical Faculty Skopje, University Clinic of Pulmonology and Allergy, Skopje, North Macedonia, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France, AQuAS, Barcelna, Spain, EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Division of Allergy, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital Holy See, Rome, Italy, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia, Allergy and Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico, Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Centich: Centre d'Expertise National des Technologies de l'Information et de la Communication pour l'Autonomie, Gérontopôle Autonomie Longévité des Pays de la Loire, Conseil Régional des Pays de la Loire, Centre d'Expertise Partenariat Europeen d'Innovation pour un Vieillissement Actif et en Bonne Sante, Nantes, France, Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR-S999, Le Kremlin Bicêtre, France, Department of Medicine and Surgery, University of Salerno, Baronissi, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, First Department of Family Medicine, Medical University of Lodz, Łódź, Poland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russian Federation, GARD, Geneva, Switzerland, Allergy and Asthma Center Westend, Berlin, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Łódź, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Mattone Internazionale Program, Veneto Region, Italy, Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, United States, Scottish Centre for Respiratory Research, Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, United Kingdom, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Pulmonary Medicine, CHU Sart-Tilman, GIGA I3 Research Group, Liege, Belgium, DG for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Barakaldo, Bizkaia, Spain, Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, University of Mississippi Medical Center, Jackson, MS, United States, Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, Department of Pediatric Pneumology and Immunology, AG Molecular Allergology and Immunomodulation, Charité Medical University, Berlin, Germany, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal, Allergy and Asthma Medical Group and Research Center, San Diego, CA, United States, Department of Physiology, CHRU, University Montpellier, PhyMedExp, INSERM U1046, CNRS, UMR 9214, Montpellier, France, Croatian Pulmonary Society, Zagreb, Croatia, National Institute of Pneumology M Nasta, Bucharest, Romania, Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia, Regione Piemonte, Turin, Italy, Mexico City, Mexico, National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syrian Arab Republic, Syrian Private University, Damascus, Syrian Arab Republic, Faculty of Medicine and Surgery, University of Medicine, La Valette, Malta, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Turin, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript Ltd., Paraparomu, New Zealand, OPC, Cambridge, United Kingdom, Johns Hopkins School of Medicine, Baltimore, MD, United States, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Scientific Centre of Children's Health under the Russian Academy of Medical Sciences, Moscow, Russian Federation, Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina, Center for Allergy and Immunology, Santa Fe, Argentina, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, Die Hautambulanz and Rothhaar Study Center, Berlin, Germany, Department of Pharmacy, University of Naples Federico II, Naples, Italy, ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic Congo, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Dept. of Otolaryngology, Nippon Medical School, Tokyo, Japan, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, Dept. of Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine and Medical University, Vienna, Austria, EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Laboratoire HP2, Université Grenoble Alpes, Grenoble, France, INSERM, U1042, CHU de Grenoble, Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal, Maladies Infectieuses et immunitaires, CHUL, Quebec City, QC, Canada, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Farmacias Holon, Lisbon, Portugal, Centre for Empowering Patients and Communities, Faulkland, Somerset, United Kingdom, Children's Hospital Srebrnjak, Zagreb, Croatia, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, University Hospital 'Sv Ivan Rilski', Sofia, Bulgaria, Academic Centre of Primary Care, University of Aberdeen, Aberdeen, United Kingdom, Research in Real-Life, Cambridge, United Kingdom, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Allergy Unit, Presidio Columbus, Catholic University of Sacred Heart, Rome, Italy, IRCCS Oasi Maria SS, Troina, Italy, Hospital de Clinicas, University of Parana, Paraná, Brazil, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Association of Finnish Pharmacists, Helsinki, Finland, Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela, Sociedad Paraguaya de Alergia Asma e Inmunologia, Asunción, Paraguay, Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, European Health Futures Forum (EHFF), Dromahair, United Kingdom, Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, Sidkkids Hospitala and Institute of Health Policy, Management and Evaluation, Toronto, Canada, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department, CIBERES and Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation, Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation, Montevideo, Uruguay, Department of Public Health and Primary Care, Leiden University Medical Center (LUMC), Leiden, Netherlands, Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy, CNR Institute of Biomedicine and Molecular Immunology A Monroy, Palermo, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Dept. of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, Cyprus International Institute for Environmental, Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital Archbishop Makarios III, Nicosia, Cyprus, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Allergy and Asthma Institute, Islamabad, Pakistan, Department of Paediatrics and Child Health, Red Cross Children's Hospital, Cape Town, South Africa, MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa, Bull DSAS, Echirolles, France, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing Institute of Otolaryngology, Beijing, China, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, and National Hospital Organization, Tokyo National Hospital, Tokyo, Japan

Abstract

Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhi-nitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement. © The Author(s) 2019.

Published
2019

46. 2019 ARIA Care pathways for allergen immunotherapy

Author

Bousquet, J. and Pfaar, O. and Togias, A. and Schünemann, H.J. and Ansotegui, I. and Papadopoulos, N.G. and Tsiligianni, I. and Agache, I. and Anto, J.M. and Bachert, C. and Bedbrook, A. and Bergmann, K.-C. and Bosnic-Anticevich, S. and Bosse, I. and Brozek, J. and Calderon, M.A. and Canonica, G.W. and Caraballo, L. and Cardona, V. and Casale, T. and Cecchi, L. and Chu, D. and Costa, E. and Cruz, A.A. and Czarlewski, W. and Durham, S.R. and Du Toit, G. and Dykewicz, M. and Ebisawa, M. and Fauquert, J.L. and Fernandez-Rivas, M. and Fokkens, W.J. and Fonseca, J. and Fontaine, J.-F. and Gerth van Wijk, R. and Haahtela, T. and Halken, S. and Hellings, P.W. and Ierodiakonou, D. and Iinuma, T. and Ivancevich, J.C. and Jacobsen, L. and Jutel, M. and Kaidashev, I. and Khaitov, M. and Kalayci, O. and Kleine Tebbe, J. and Klimek, L. and Kowalski, M.L. and Kuna, P. and Kvedariene, V. and La Grutta, S. and Larenas-Linemann, D. and Lau, S. and Laune, D. and Le, L. and Lodrup Carlsen, K. and Lourenço, O. and Malling, H.-J. and Marien, G. and Menditto, E. and Mercier, G. and Mullol, J. and Muraro, A. and O’Hehir, R. and Okamoto, Y. and Pajno, G.B. and Park, H.-S. and Panzner, P. and Passalacqua, G. and Pham-Thi, N. and Roberts, G. and Pawankar, R. and Rolland, C. and Rosario, N. and Ryan, D. and Samolinski, B. and Sanchez-Borges, M. and Scadding, G. and Shamji, M.H. and Sheikh, A. and Sturm, G.J. and Todo Bom, A. and Toppila-Salmi, S. and Valentin-Rostan, M. and Valiulis, A. and Valovirta, E. and Ventura, M.-T. and Wahn, U. and Walker, S. and Wallace, D. and Waserman, S. and Yorgancioglu, A. and Zuberbier, T. and the ARIA Working Group, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA : Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Hospital Quirónsalud Bizkaia, Bilbao, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Social Medicine, Faculty of Medicine, University of Crete and International Primary Care Respiratory Group, Crete, Greece, Faculty of Medicine, Transylvania University, Brasov, Romania, Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Comprehensive Allergy Centre, Member of GA2LEN, Humboldt-Uniersität zu Berlin, Berlin, Germany, Woolcock Institute of Medical Research, Woolcock Emphysema Centre and Local Health District, University of Sydney, Glebe, NSW, Australia, Allergist, La Rochelle, France, Imperial College London - National Heart and Lung Institute, Royal Brompton Hospital NHS, London, United Kingdom, Personalized Medicine Clinic Asthma & Allergy, Humanitas Research Hospital, Humanitas University, Milan, Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Guy's and st Thomas' NHS Trust, Kings College London, London, United Kingdom, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, Unité de pneumo-allergologie de l'enfant, pôle pédiatrique, CHU de Clermont-Ferrand-Estaing, Clermont-Ferrand, France, Allergy Department, IdISSC, Hospital Clinico San Carlos, Madrid, Spain, Department of Otorhinolaryngology, Academic Medical Centres, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Allergist, Reims, France, Department of Internal Medicine, Section of Allergology, Erasmus MC, Rotterdam, Netherlands, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Allergy Learning and Consulting, Copenhagen, Denmark, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, National Research Center, Moscow, Russian Federation, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Allergy & Asthma Center Westend, Berlin, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Faculty of Medicine, Institute of Clinical medicine, Clinic of Chest diseases and Allergology, Vilnius University, Vilnius, Lithuania, Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Danish Allergy Centre, University of Copenhagen, Copenhagen, Denmark, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Département de l’Information Médicale, Unité Médico-Economie, University Hospital, Montpellier, France, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Genoa, Italy, Allergy Department, Pasteur Institute, Paris, France, David Hide Centre, St Mary's Hospital, Isle of Wight and University of Southampton, Southampton, United Kingdom, Department of Pediatrics, Nippon Medical School, Tokyo, Japan, Association Asthme et Allergie, Paris, France, Hospital de Clinicas, University of Parana, Parana, Brazil, Allergy and Respiratory Research Group, Medical School, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, The Royal National TNE Hospital, University College London, London, United Kingdom, Immunomodulation and Tolerance Group, Imperial College London, London, United Kingdom, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria, Outpatient Allergy Clinic Reumannplatz, Vienna, Austria, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Allergist, Montevideo, Uruguay, Clinic of Children's Diseases, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, Department of Public Health, Institute of Health Sciences, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, Terveystalo Allergy Clinic, University of Turku, Turku, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Pediatric Department, Charité, Berlin, Germany, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, and Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey

Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2019

47. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 1)

Author

Bousquet, J. Pham-Thi, N. Bedbrook, A. Agache, I. Annesi-Maesano, I. Ansotegui, I. Anto, J.M. Bachert, C. Benveniste, S. Bewick, M. Billo, N. Bosnic-Anticevich, S. Bosse, I. Brusselle, G. Calderon, M.A. Canonica, G.W. Caraballo, L. Cardona, V. Carriazo, A.M. Cash, E. Cecchi, L. Chu, D.K. Colgan, E. Costa, E. Cruz, A.A. Czarlewski, W. Durham, S. Ebisawa, M. Erhola, M. Fauquert, J.-L. Fokkens, W.J. Fonseca, J.A. Guldemond, N. Iinuma, T. Illario, M. Klimek, L. Kuna, P. Kvedariene, V. Larenas-Linneman, D. Laune, D. Le, L.T.T. Lourenço, O. Malva, J.O. Marien, G. Menditto, E. Mullol, J. Münter, L. Okamoto, Y. Onorato, G.L. Papadopoulos, N.G. Perala, M. Pfaar, O. Phillips, A. Phillips, J. Pinnock, H. Portejoie, F. Quinones-Delgado, P. Rolland, C. Rodts, U. Samolinski, B. Sanchez-Borges, M. Schünemann, H.J. Shamji, M. Somekh, D. Togias, A. Toppila-Salmi, S. Tsiligianni, I. Usmani, O. Walker, S. Wallace, D. Valiulis, A. Van Der Kleij, R. Ventura, M.T. Williams, S. Yorgancioglu, A. Zuberbier, T.

Published
2019

48. ARIA guideline 2019: treatment of allergic rhinitis in the German health system

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Abstract

Background: The number of patients affected by allergies is increasing worldwide. The resulting allergic diseases are leading to significant costs for health care and social systems. Integrated care pathways are needed to enable comprehensive care within the national health systems. The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative develops internationally applicable guidelines for allergic respiratory diseases. Methods: ARIA serves to improve the care of patients with allergies and chronic respiratory diseases. In collaboration with other international initiatives, national associations and patient organizations in the field of allergies and respiratory diseases, real-life integrated care pathways have been developed for a digitally assisted, integrative, individualized treatment of allergic rhinitis (AR) with comorbid asthma. In the present work, these integrated care pathways have been adapted to the German situation and health system. Results: The present ICP (integrated care pathways) guideline covers key areas of the care of AR patients with and without asthma. It includes the views of patients and other healthcare providers. Discussion: A comprehensive ICP guideline can reflect real-life care better than traditional guideline models. © 2019, The Author(s).

Published
2019

49. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

Author

Bousquet, J.J. (J. Jean), Schünemann, H.J. (Holger), Togias, A., Erhola, M. (Marina), Hellings, P.W. (Peter), Zuberbier, T. (Torsten), Agache, I. (Ioana), Ansotegui, I.J. (I.), Anto, J.M. (Josep), Bachert, C. (Claus), Becker, S. (Sven), Bedolla-Barajas, M. (Martin), Bewick, M. (Michael), Bosnic-Anticevich, S. (Sinthia), Bosse, I. (Isabelle), Boulet, L.P., Bourrez, J.M. (Jean Marc), Brusselle, G.G. (Guy), Chavannes, N.H. (Nicolas), Costa, E. (Elisio), Cruz, A.A. (Alvaro), Czarlewski, W. (Wienczyslawa), Fokkens, W.J. (Wytske), Fonseca, J.A. (Joao A.), Gaga, M. (Mina), Haahtela, T. (Tari), Illario, M. (Maddalena), Klimek, L. (Ludger), Kuna, P. (Piotr), Kvedariene, V. (Violeta), Le, L.T., Larenas-Linnemann, D. (Désirée), Laune, D. (Daniel), Lourenço, O.M. (Olga M.), Menditto, E. (Enrica), Mullol, J. (Joaquin), Okamoto, Y. (Yashitaka), Papadopoulos, N., Pham-Thi, N. (Nhân), Picard, R. (Robert), Pinnock, H. (Hilary), Roche, N. (Nicolas), Roller-Wirnsberger, R.E. (Regina E.), Rolland, C. (Christine), Samolinski, B. (Boleslaw), Sheikh, A. (Aziz), Toppila-Salmi, S. (Sanna), Tsiligianni, I.G. (Ioanna G), Valiulis, A. (Arunas), Valovirta, E. (Erkka), Vasankari, T. (Tuula), Ventura, M.-T. (Maria-Teresa), Walker, S. (Samantha), Williams, S. (Sian), Akdis, C.A. (Cezmi A.), Annesi-Maesano, I. (Isabella), Arnavielhe, S. (Sylvie), Basagaña, X. (Xavier), Bateman, E.D. (Eric), Bedbrook, A. (Anna), Bennoor, K.S. (K.), Benveniste, S. (Samuel), Bergmann, K.-C. (Karl-Christian), Bialek, S. (Slawomir), Billo, N. (Nils), Bindslev-Jensen, C. (Carsten), Bjermer, L. (Leif), Blain, H. (Hubert), Bonini, M. (Matteo), Bonniaud, P. (Philippe), Bouchard, J. (Jacques), Briedis, V. (Vitalis), Brightling, C.E. (Christofer E.), Brozek, J., Buhl, R. (Roland), Buonaiuto, R. (Roland), Canonica, G.W. (Giorgo W.), Cardona, D. (Doris), Carriazo, A.M. (Ana M.), Carr, W.W. (Warner), Cartier, C. (Christine), Casale, T.B. (Thomas), Cecchi, L. (Lorenzo), Cepeda Sarabia, A.M. (Alfonso M.), Chkhartishvili, E. (Eka), Chu, D.K. (Derek K.), Cingi, C. (Cemal), Colgan, E. (Elaine), De Sousa, J.C. (Jaime Correia), Courbis, A.L. (Anne Lise), Custovic, A. (Adnan), Cvetkosvki, B. (Biljana), Damato, G. (Gennaro), Da Silva, J. (Jane), Dantas, C. (Carina), Dokic, D. (D.), Dauvilliers, Y. (Yves), Dedeu, A. (Antoni), De Feo, G. (Giulia), Devillier, P. (Philippe), Di Capua, S. (Stefania), Dykewickz, M. (Marc), Dubakiene, R. (R.), Ebisawa, M. (Motohiro), El-Gamal, Y. (Y.), Eller, E. (Esben), Emuzyte, R., Farrell, J. (John), Fink-Wagner, A. (Antjie), Fiocchi, A. (Alessandro), Fontaine, J.F. (Jean F.), Gemicioǧlu, B. (Bilun), Schmid-Grendelmeir, P. (Peter), Gamkrelidze, A. (Amiran), Garcia-Aymerich, J. (Judith), Gomez, M. (Maximiliano), Diaz, S.G. (Sandra González), Gotua, M. (M.), Guldemond, N. (Nick), Guzmán, M.A. (M.), Hajjam, J. (Jawad), O'Hourihane, J.B. (John B.), Humbert, M. (Marc), Iaccarino, G. (Guido), Ierodiakonou, D. (Despo), Ivancevich, J.C. (Juan), Joos, G.F. (Guy), Jung, K.-S. (Ki-Suck), Jutel, M. (M.), Kaidashev, I. (Igor), Kalayci, O. (Omer), Kardas, P. (Przemyslaw), Keil, M. (Mark), Khaitov, M. (Mussa), Khaltaev, N., Kleine-Tebbe, J. (Jörg), Kowalski, M.L., Kritikos, V. (Vicky), Kull, C.A. (Christian), Leonardini, L. (Lisa), Lieberman, A.P. (Andrew), Lipworth, B., Lødrup Carlsen, K.C. (K. C.), Loureiro, C.C. (Claudia C.), Louis, R. (Renaud), Mair, A. (Alpana), Marien, G. (Gert), Mahboub, B., Malva, J. (Joao), Manning, P. (Patrick), De Manuel Keenoy, E. (Esteban), Marshall, G.D., Masjedi, M.R. (Mohamed R.), Maspero, J.F. (Jorge F.), Mathieu-Dupas, E. (Eve), Matricardi, P.M. (Poalo M.), Melén, E. (Eric), Melo-Gomes, E. (Elisabete), Meltzer, E.O., Mercier, J. (Jacques), Miculinic, N. (Neven), Mihaltan, F. (Florin), Milenkovic, B. (Branislava), Moda, G. (Giuliana), Mogica-Martinez, M.-D. (Maria-Dolores), Mohammad, Y., Montefort, S. (Steve), Monti, R. (Ricardo), Morais-Almeida, M. (Mario), Mösges, R. (Ralph), Münter, L. (Lars), Muraro, A. (Antonella), Murray, R. (Ruth), Naclerio, R., Napoli, L. (Luigi), Namazova-Baranova, L. (Leila), Neffen, H. (Hugo), Nekam, K. (Kristoff), Neou, A. (A.), Novellino, E. (Enrico), Nyembue, D. (Dieudonné), O'Hehir, R. (Robin), Ohta, K., Okubo, K. (Kimi), Onorato, G. (Gabrielle), Ouedraogo, S., Pali-Schöll, I. (I.), Palkonen, S. (Susanna), Panzner, P. (P.), Park, H.-S. (Hae-Sim), Pépin, J.-L. (Jean-Louis), Pereira, A.-M. (Ana-Maria), Pfaar, O. (Oliver), Paulino, E. (Ema), Phillips, J. (Jim), Plavec, D. (Davor), Popov, T.A. (Ted A.), Portejoie, F. (Fabienne), Price, D. (David), Prokopakis, E.P. (Emmanuel P.), Pugin, B. (Benoit), Raciborski, F. (Filip), Rajabian-Söderlund, R. (Rojin), Reitsma, S. (Sietze), Rodo, X. (Xavier), Romano, A., Rosario, N. (Nelson), Rottem, M. (Menahenm), Ryan, D. (Dermot), Salimäki, J. (Johanna), Sanchez-Borges, M.M. (Mario M.), Sisul, J.C. (J.), Solé, D. (Dirceu), Somekh, D. (David), Sooronbaev, T. (Talant), Sova, M. (Milan), Spranger, O., Stellato, C. (Cristina), Stelmach, R. (Rafael), Ulrik, C.S., Thibaudon, M. (Michel), To, T. (Teresa), Todo Bom, A., Tomazic, P.V. (Peter V.), Valero, A.A. (Antonio A.), Valenta, R. (Rudolph), Valentin-Rostan, M. (Marylin), Van Der Kleij, R.M. (Rianne Mjj), Vandenplas, O. (Olivier), Vezzani, G. (Giorgio), Viart, F. (Frédéric), Viegi, G., Wallace, D. (D.), Wagenmann, M. (Martin), Wang, D.Y. (De Y.), Waserman, S. (Susan), Wickman, M. (Magnus), Williams, D., Wong, G. (G.), Wroczynski, P. (Piotr), Yiallouros, P.K. (P.), Yorgancioglu, A. (Arzu), Yusuf, O.M. (Osman), Zar, H.J. (Heahter J.), Zeng, S. (Stéphane), Zernotti, M., Zhang, L. (Luo), Zhong, N.S. (Nan S.), Zidarn, M. (Mihaela), Bousquet, J.J. (J. Jean), Schünemann, H.J. (Holger), Togias, A., Erhola, M. (Marina), Hellings, P.W. (Peter), Zuberbier, T. (Torsten), Agache, I. (Ioana), Ansotegui, I.J. (I.), Anto, J.M. (Josep), Bachert, C. (Claus), Becker, S. (Sven), Bedolla-Barajas, M. (Martin), Bewick, M. (Michael), Bosnic-Anticevich, S. (Sinthia), Bosse, I. (Isabelle), Boulet, L.P., Bourrez, J.M. (Jean Marc), Brusselle, G.G. (Guy), Chavannes, N.H. (Nicolas), Costa, E. (Elisio), Cruz, A.A. (Alvaro), Czarlewski, W. (Wienczyslawa), Fokkens, W.J. (Wytske), Fonseca, J.A. (Joao A.), Gaga, M. (Mina), Haahtela, T. (Tari), Illario, M. (Maddalena), Klimek, L. (Ludger), Kuna, P. (Piotr), Kvedariene, V. (Violeta), Le, L.T., Larenas-Linnemann, D. (Désirée), Laune, D. (Daniel), Lourenço, O.M. (Olga M.), Menditto, E. (Enrica), Mullol, J. (Joaquin), Okamoto, Y. (Yashitaka), Papadopoulos, N., Pham-Thi, N. (Nhân), Picard, R. (Robert), Pinnock, H. (Hilary), Roche, N. (Nicolas), Roller-Wirnsberger, R.E. (Regina E.), Rolland, C. (Christine), Samolinski, B. (Boleslaw), Sheikh, A. (Aziz), Toppila-Salmi, S. (Sanna), Tsiligianni, I.G. (Ioanna G), Valiulis, A. (Arunas), Valovirta, E. (Erkka), Vasankari, T. (Tuula), Ventura, M.-T. (Maria-Teresa), Walker, S. (Samantha), Williams, S. (Sian), Akdis, C.A. (Cezmi A.), Annesi-Maesano, I. (Isabella), Arnavielhe, S. (Sylvie), Basagaña, X. (Xavier), Bateman, E.D. (Eric), Bedbrook, A. (Anna), Bennoor, K.S. (K.), Benveniste, S. (Samuel), Bergmann, K.-C. (Karl-Christian), Bialek, S. (Slawomir), Billo, N. (Nils), Bindslev-Jensen, C. (Carsten), Bjermer, L. (Leif), Blain, H. (Hubert), Bonini, M. (Matteo), Bonniaud, P. (Philippe), Bouchard, J. (Jacques), Briedis, V. (Vitalis), Brightling, C.E. (Christofer E.), Brozek, J., Buhl, R. (Roland), Buonaiuto, R. (Roland), Canonica, G.W. (Giorgo W.), Cardona, D. (Doris), Carriazo, A.M. (Ana M.), Carr, W.W. (Warner), Cartier, C. (Christine), Casale, T.B. (Thomas), Cecchi, L. (Lorenzo), Cepeda Sarabia, A.M. (Alfonso M.), Chkhartishvili, E. (Eka), Chu, D.K. (Derek K.), Cingi, C. (Cemal), Colgan, E. (Elaine), De Sousa, J.C. (Jaime Correia), Courbis, A.L. (Anne Lise), Custovic, A. (Adnan), Cvetkosvki, B. (Biljana), Damato, G. (Gennaro), Da Silva, J. (Jane), Dantas, C. (Carina), Dokic, D. (D.), Dauvilliers, Y. (Yves), Dedeu, A. (Antoni), De Feo, G. (Giulia), Devillier, P. (Philippe), Di Capua, S. (Stefania), Dykewickz, M. (Marc), Dubakiene, R. (R.), Ebisawa, M. (Motohiro), El-Gamal, Y. (Y.), Eller, E. (Esben), Emuzyte, R., Farrell, J. (John), Fink-Wagner, A. (Antjie), Fiocchi, A. (Alessandro), Fontaine, J.F. (Jean F.), Gemicioǧlu, B. (Bilun), Schmid-Grendelmeir, P. (Peter), Gamkrelidze, A. (Amiran), Garcia-Aymerich, J. (Judith), Gomez, M. (Maximiliano), Diaz, S.G. (Sandra González), Gotua, M. (M.), Guldemond, N. (Nick), Guzmán, M.A. (M.), Hajjam, J. (Jawad), O'Hourihane, J.B. (John B.), Humbert, M. (Marc), Iaccarino, G. (Guido), Ierodiakonou, D. (Despo), Ivancevich, J.C. (Juan), Joos, G.F. (Guy), Jung, K.-S. (Ki-Suck), Jutel, M. (M.), Kaidashev, I. (Igor), Kalayci, O. (Omer), Kardas, P. (Przemyslaw), Keil, M. (Mark), Khaitov, M. (Mussa), Khaltaev, N., Kleine-Tebbe, J. (Jörg), Kowalski, M.L., Kritikos, V. (Vicky), Kull, C.A. (Christian), Leonardini, L. (Lisa), Lieberman, A.P. (Andrew), Lipworth, B., Lødrup Carlsen, K.C. (K. C.), Loureiro, C.C. (Claudia C.), Louis, R. (Renaud), Mair, A. (Alpana), Marien, G. (Gert), Mahboub, B., Malva, J. (Joao), Manning, P. (Patrick), De Manuel Keenoy, E. (Esteban), Marshall, G.D., Masjedi, M.R. (Mohamed R.), Maspero, J.F. (Jorge F.), Mathieu-Dupas, E. (Eve), Matricardi, P.M. (Poalo M.), Melén, E. (Eric), Melo-Gomes, E. (Elisabete), Meltzer, E.O., Mercier, J. (Jacques), Miculinic, N. (Neven), Mihaltan, F. (Florin), Milenkovic, B. (Branislava), Moda, G. (Giuliana), Mogica-Martinez, M.-D. (Maria-Dolores), Mohammad, Y., Montefort, S. (Steve), Monti, R. (Ricardo), Morais-Almeida, M. (Mario), Mösges, R. (Ralph), Münter, L. (Lars), Muraro, A. (Antonella), Murray, R. (Ruth), Naclerio, R., Napoli, L. (Luigi), Namazova-Baranova, L. (Leila), Neffen, H. (Hugo), Nekam, K. (Kristoff), Neou, A. (A.), Novellino, E. (Enrico), Nyembue, D. (Dieudonné), O'Hehir, R. (Robin), Ohta, K., Okubo, K. (Kimi), Onorato, G. (Gabrielle), Ouedraogo, S., Pali-Schöll, I. (I.), Palkonen, S. (Susanna), Panzner, P. (P.), Park, H.-S. (Hae-Sim), Pépin, J.-L. (Jean-Louis), Pereira, A.-M. (Ana-Maria), Pfaar, O. (Oliver), Paulino, E. (Ema), Phillips, J. (Jim), Plavec, D. (Davor), Popov, T.A. (Ted A.), Portejoie, F. (Fabienne), Price, D. (David), Prokopakis, E.P. (Emmanuel P.), Pugin, B. (Benoit), Raciborski, F. (Filip), Rajabian-Söderlund, R. (Rojin), Reitsma, S. (Sietze), Rodo, X. (Xavier), Romano, A., Rosario, N. (Nelson), Rottem, M. (Menahenm), Ryan, D. (Dermot), Salimäki, J. (Johanna), Sanchez-Borges, M.M. (Mario M.), Sisul, J.C. (J.), Solé, D. (Dirceu), Somekh, D. (David), Sooronbaev, T. (Talant), Sova, M. (Milan), Spranger, O., Stellato, C. (Cristina), Stelmach, R. (Rafael), Ulrik, C.S., Thibaudon, M. (Michel), To, T. (Teresa), Todo Bom, A., Tomazic, P.V. (Peter V.), Valero, A.A. (Antonio A.), Valenta, R. (Rudolph), Valentin-Rostan, M. (Marylin), Van Der Kleij, R.M. (Rianne Mjj), Vandenplas, O. (Olivier), Vezzani, G. (Giorgio), Viart, F. (Frédéric), Viegi, G., Wallace, D. (D.), Wagenmann, M. (Martin), Wang, D.Y. (De Y.), Waserman, S. (Susan), Wickman, M. (Magnus), Williams, D., Wong, G. (G.), Wroczynski, P. (Piotr), Yiallouros, P.K. (P.), Yorgancioglu, A. (Arzu), Yusuf, O.M. (Osman), Zar, H.J. (Heahter J.), Zeng, S. (Stéphane), Zernotti, M., Zhang, L. (Luo), Zhong, N.S. (Nan S.), and Zidarn, M. (Mihaela)

Abstract

Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhi-nitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results